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ABSTRACT OF THE DISSERTATION 
 
Structurally Diverse Cu-64-Labeled RGD Peptide Conjugates  
for PET imaging of αvβ3 Expression 
by 
Ashley Lauren Fiamengo 
Doctor of Philosophy in Chemistry 
Washington University in St. Louis, 2009 
Professor Carolyn J. Anderson, Chair 
 
Radiolabeled receptor-binding peptides have emerged as an important class of 
radiopharmaceuticals for diagnostic imaging and cancer therapy. Following radionuclide 
labeling, the specific receptor-binding properties of the ligand can be exploited to guide 
the radioactivity to tissues expressing a particular receptor. This dissertation reports on 
the development of integrin αvβ3–targeting radiopharmaceuticals for medical imaging 
applications from the perspective of both the radiometal-labeled chelator as well as the 
targeting peptide. Several macrocyclic copper(II) chelators have been studied with the 
goal of improving kinetic and in vivo stability. Structurally diverse bifunctional RGD 
(arginine-glycine-aspartic acid) peptides were investigated for αvβ3 integrin affinity in vitro 
and in vivo. The goal of accomplishing higher binding affinity through multivalency has 
been pursued by evaluating the binding affinity of nanoparticles presenting multiple 
peptides on their surface. 
Copper radionuclides have been the subject of considerable research effort 
because they offer a varying range of half-lives and positron energies, making them 
useful for diagnostic imaging and/or targeted radiotherapy. Ensuring the stability of metal 
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complexes in vivo remains a challenge in the development of radiometal-based 
radiopharmaceuticals. Reported here are data on the in vitro and in vivo evaluation of 
three macrocyclic chelators, C3B-DO2A, CB-TR2A, and NOTA. These studies were 
performed to improve Cu(II) complexation kinetics while retaining the high in vivo 
stability of our lead chelating agent, CB-TE2A. Optimal radiolabeling conditions were 
established for the 64Cu-labeled radiometal chelators and their in vivo biodistribution and 
excretion were studied in normal rats. 
Integrin αvβ3 is upregulated in tumor vasculature, osteoclasts, and areas of 
collateral circulation following ischemic injury. A series of structurally diverse bifunctional 
RGD (arginine-glycine-aspartic acid) peptides were investigated for αvβ3 affinity in vitro 
and in vivo. The RGD-peptide analogs were screened for affinity to the αvβ3 integrin and 
specificity compared to αvβ5 and αIIbβ3. Extent of internalization of these peptides by an 
αvβ3 expressing cell line, U87MG human glioblastoma cells, was determined. The 
compounds were screened via biodistribution studies and microPET imaging of a murine 
U87MG tumor model. 
Polyvalence has known to have a profound effect on receptor-binding affinity and 
in vivo kinetics of radiolabeled multimers. The goal of accomplishing higher binding 
affinity through multivalency has been pursued by evaluating the binding affinity of shell 
cross-linked (SCK) nanoparticles presenting multiple RGD peptides on their surface. 
Difficulties encountered in obtaining nanoparticles with high levels of bioavailable 
targeting peptide on the surface led to a systematic study of methods of shell 
functionalization and particle purification with chemical, physical, and biological 
evaluation of each compound.  
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The development of radiometal-labeled peptides is a relatively slow process, thus 
in this research, optimization of various aspects was studied in parallel. Each chapter 
presents a small contribution, but the knowledge gained from these studies can be taken 
together to produce radiopharmaceuticals with optimal properties—high in vivo stability, 
high uptake in tumors, low uptake in non-target tissues, and rapid blood clearance, 
preferably through renal excretion. 
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Introduction 
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Molecular Imaging 
 Molecular imaging has distinguished itself as an interdisciplinary field drawing 
from chemistry, biology, physics, and medicine. The fact that a collaborative effort 
among several professional societies was under taken to define molecular imaging 
emphasizes its broad reach. “Molecular imaging is the visualization, characterization, 
and measurement of biological processes at the molecular and cellular levels in 
human and other living systems. To elaborate: Molecular imaging typically includes 
2- or 3-dimensional imaging as well as quantification over time. The techniques 
include radiotracer imaging/nuclear medicine, MR imaging, MR spectroscopy, optical 
imaging, ultrasound, and others.”1 It has impacted clinical medicine and 
pharmaceutical development. Physicians can generate high-resolution images of the 
human body non-invasively, diagnose ailments, and prescribe or monitor treatment 
regimens based on them. Scientists involved in drug discovery can accelerate the 
screening process in pre-clinical drug development. Molecular imaging can facilitate 
determinations of desired and undesired pharmaceutical side effects, analyze drug-
target interactions, and evaluate delivery absorption, distribution, metabolism, and 
elimination in vivo. Its utility in studying drug action, establishing dosing regimens 
and treatment strategies will eventually provide the means to accomplish 
“personalized medicine” by monitoring individual response to drug delivery.2 
 Molecular imaging differs from traditional imaging in that biomarkers are used 
to help image particular targets or pathways. Biomarkers are characteristics that are 
objectively and quantitatively measured and evaluated as an indicator of normal 
biological processes, pathogenic processes, or pharmacologic responses to a 
therapeutic intervention. They interact chemically with specific components in their 
surroundings allowing imaging of physiological changes, altering the image 
according to molecular changes occurring within the area of interest. This process is 
markedly different from older methods of imaging, such as x-ray and magnetic 
resonance imaging (MRI), which primarily image differences in qualities such as 
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density or water content. The ability to image fine molecular changes opens up 
numerous exciting possibilities for medical and research applications. Furthermore, 
molecular imaging allows for quantitative tests, imparting a greater degree of 
objectivity to these imaging studies. 
 Nuclear medicine is a medical field that employs molecular imaging through 
the use of radioactive agents (e.g. radiopharmaceuticals) for the purpose of 
diagnosis and therapy of disease. By imaging the distribution of radioactivity in the 
subject, physicians can non-invasively provide useful information about metabolism, 
blood flow, inflammation, and receptor status as well as location, size, and extent of 
diseased tissues. Radiopharmaceuticals are created by the incorporation of 
radionuclides into compounds tailored for biological targeting. This non-invasive 
imaging relies on the external detection of the emitted radiation by cameras 
surrounding the subject. The intrinsic properties of the radionuclide utilized determine 
the value of an agent for imaging or therapy, in addition to determining the 
appropriate imaging modality—gamma camera, single photon emission computed 
tomography (SPECT) or positron emission tomography (PET). A gamma camera 
gives planar images, whereas SPECT and PET provide three-dimensional images. 
In the research described here, PET imaging, which utilizes positron-emitting 
radionuclides, is used to investigate in vivo biological processes non-invasively.  
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Positron Emission Tomography  
 PET allows for non-invasive construction of static anatomical images as well 
as the collection of dynamic, real-time images of a biochemical process. PET images 
are obtained following intravenous (IV) injection of a positron (β+) emitting 
radiopharmaceutical whose biochemical behavior and biological distribution are well 
characterized. The development of novel positron-emitting radiopharmaceuticals with 
desirable clearance and pharmacokinetic properties is a growing field of research.3 
 Radioactive decay occurs as part of the process of balancing an unstable 
nucleus’ proton/neutron ratio. Proton-rich isotopes undergo a process that will lower 
this ratio and result in a stable nucleus. One method is through the addition of energy 
to convert a proton (p) into a neutron (n), neutrino (υ) and a positron (β+) (Equation 
1).  
+++→ βνnp   (Eq. 1) 
The new element recoils from the event, and the positron and neutrino are emitted at 
high speed. The positron, a positively charged electron, collides with electrons as it 
travels through the surrounding matter losing kinetic energy. Once most of the 
energy has been lost, the positron associates with an electron, which has an 
opposite charge but equal mass, and both particles annihilate. The particles’ masses 
are converted into energy in the form of two 511 keV photons, emitted in opposite 
directions, almost 180º apart from each other (Figure 1). These annihilation photons 
can be detected by coincidence circuitry consisting of a solid scintillation crystal 
coupled to a photomultiplier tube (PMT). The energy of the positron determines the 
distance traveled by the particle prior to annihilation. Higher ejection energy 
corresponds to a greater distance traveled before annihilation. This distance, known 
as the positron range, affects image resolution. 
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Figure 1. A positron is emitted from an unstable proton-rich nucleus. After traveling a 
short distance, it annihilates upon contact with an electron. This releases two 
photons approximately 180° apart. 
 
 A PET scanner consists of an array of detectors surrounding the subject, 
connected through coincidence circuitry. A decay event is recorded when a pair of 
photons are received at connected detectors within a certain time frame (Figure 2). 
The exact site of the annihilation is unknown, but by acquiring a large number of 
coincidence events recorded across all detector combinations, sufficient information 
is obtained for complex computer algorithms to reconstruct the numerous events that 
have been registered into an image with information on the spatial distribution of 
radioactivity as a function of time. Several factors affect image resolution, including 
positron range, photon attenuation, and random coincidences from scattered and 
random photons. Once corrections for photon attenuation and random, scattered 
radiation have been made, the measured tissue radioactivity can be reported in 
absolute units, such as Becquerel (Bq)/mL. Correlation of PET images with 
anatomical imaging modalities, such as CT and MRI, can aid in accurate 
identification of tissues with enhanced uptake.4 
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Gamma rays
 
Figure 2. Cartoon of a human PET scanner. A circular array of detectors surrounds 
the patient and records sets of co-incident photon pairs. 
 
 Biomedical research usually involves extensive pre-clinical evaluation prior to 
approval for human use. Animal models are employed in radiopharmaceutical 
development. Human PET scanners have insufficient resolution for small animal, 
such as rodent, imaging. A small animal PET scanner called microPET has better 
sensitivity and image resolution for imaging in rodent or other small animal models.5 
Additionally, microPET systems are more compact and cost less than clinical PET 
systems. As with human PET images, microPET and micro-computed tomography 
(microCT) images can be co-registered to enhance anatomical resolution in small 
animal imaging.  
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Targeted Radiopharmaceuticals  
 Radiopharmaceuticals are radioactive compounds used in nuclear medicine 
for diagnosis and therapy. There are two broad categories of radiopharmaceuticals: 
substrate specific and non-substrate specific agents. The more common, substrate-
specific radiopharmaceuticals are designed to target a specific biological process, 
receptor or other type of protein expressed in distinct regions of the body. 
Radiolabeled peptides have been extensively investigated for targeting over-
expressed receptors on tumor cells and at sites of cardiovascular injury and repair. 
Targeted radiopharmaceuticals are useful for diagnostic imaging as well as for 
predicting response to a therapeutic regimen such as chemotherapy or targeted 
radiotherapy. Depending on the mode of radioactive decay of the radionuclide, these 
or analogous compounds can also be used for targeted radiotherapy. 
 Selection of the proper radionuclide in radiopharmaceutical design is 
important and depends on several factors. The half-life should allow for sufficient 
uptake and decay to yield contrast and quality images.6 The mode of decay and 
energies of the radionuclide emission should be suitable for detection by the chosen 
imaging modality. Radiopharmaceuticals incorporating β+ or γ emitting radionuclides 
are useful for PET or SPECT imaging, respectively. Cost and availability should also 
be considered. 
 There are a variety of commonly used positron emitting radionuclides with 
various energy profiles and half-lives. The most widely used isotope for PET 
radiopharmaceuticals is 18F due to practicality of transport with a half-life of 109.8 min 
and ideal average β+ energy.7 The only FDA approved tracer for oncologic imaging is 
[18F]2-fluoro-D-deoxyglucose (FDG), a radiolabeled glucose derivative.8 FDG, the 
most common targeted PET imaging radiopharmaceutical, is taken up by glucose-
utilizing cells and retained following phosphorylation by hexokinase. It is used for 
studying cerebral, myocardial, and tumor glucose metabolism; however, the 
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specificity of FDG is compromised due to uptake by inflamed and infected tissues as 
well as by metabolically active tumors.  
 Radiolabeled peptides are good alternatives to FDG, as certain peptide-
based agents specifically target receptors that are overexpressed by specific tumor 
cells. Peptides have many of the favorable characteristics of small molecule 
radiotracers, namely rapid blood clearance and tissue penetration, and low 
antigenicity. However, 18F cannot be readily incorporated into peptides and 
antibodies as targeted radioligands.8 The short 119 min half-life of 18F, typical 2 h 
synthesis that includes HPLC purification, and resultant low yield are not ideal for 
radiopharmaceutical production. Due to the larger size of peptides, metals can be 
more readily attached to peptides via coordination by covalently bound chelators. 
This additional functional group typically has well established radiolabeling chemistry 
and its attachment often has no significant effect on peptide binding to target 
receptors. Also, the diversity of half-lives of radiometals allows the physical half-life 
of the isotope to be matched to the biological half-life of the radiopharmaceutical.9 
Therefore, the development of radiometal-based agents is an active area of 
research.  
 
Copper-64 
 Copper radionuclides have been the subject of considerable research effort 
because they offer a varying range of half-lives and positron energies, making them 
useful for diagnostic imaging and/or targeted radiotherapy (Table 1).10, 11 Their half-
lives range from 10 minutes to 62 hours; they decay by positron (β+) and/or beta-
minus (β-) emission. The biodistribution of these copper radionuclides can be 
assessed externally via clinical positron or gamma imaging techniques. 
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Table 1. Decay characteristics of copper radionuclides.8 
Isotope t1/2 β- MeV (%) β+ MeV (%) EC (%) γ MeV (%) 
60Cu 23.4 min --- 2.00 (69%)  
3.00 (18%) 
3.92 (6%) 
7.4% 0.511 (186%) 
0.85 (15%) 
1.33 (80%) 
1.76 (52%) 
2.13 (6%) 
61Cu 3.32 h --- 1.22 (60%) 40% 0.284 (12%) 
0.38 (3%) 
0.511 (120%) 
62Cu 9.76 min --- 2.91 (97%) 2% 0.511 (194%) 
64Cu 12.7 h 0.573 (38.4%) 0.655 (17.8%) 41% 0.511 (34.8%) 
1.35 (0.6%) 
67Cu 62.0 h 0.395 (45%) 
0.484 (35%) 
0.577 (20%) 
--- --- 0.184 (40%) 
 
 
 Positron-emitting radionuclides are produced on either accelerators or 
cyclotrons. Typically, a target material is bombarded with a proton beam to produce 
a (p, n) nuclear reaction. A proton is incorporated into the nucleus followed by the 
release of a neutron, resulting in a proton rich, unstable radionuclide that undergoes 
β
+
 decay, as previously described. At Washington University, no-carrier-added 64Cu 
is produced on a biomedical cyclotron in high yield and high specific activity.12 Briefly, 
a gold disk target electroplated with enriched 64Ni is irradiated with 14.5 MeV protons 
on a CS-15 biomedical cyclotron. The target is introduced to an automated 
processing system, and the nickel is dissolved in heated 6 M hydrochloric acid 
(HCl).13 The dissolved nickel is loaded on an ion chromatography column and 
recovered for recycling. Copper-64 is eluted off using 0.5 M HCl and blown down 
under argon.14 
Copper-64 has a long history of applications as a biomedical tracer because 
of its longer half-life and short positron range. The 12.7 hour half-life allows for 
distribution of this nuclide from regional production centers to imaging centers that do 
not have direct access to a cyclotron. Copper-64 decays 17.8% by positron emission 
and has a β+ maximum energy of 0.655 MeV with an average energy of 0.28 MeV. It 
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also decays by electron capture and β-; therefore, it has been studied as both a 
diagnostic and therapeutic radionuclide.15 The β+ maximum energy of 0.655 MeV is 
similar to 18F, so the resulting PET images are of high quality.16 
 Copper coordination chemistry is well described in the literature, facilitating 
the development of copper-based radiopharmaceuticals.12 Copper is a first-row 
transition metal that primarily exists in two oxidation states: Cu(I) and Cu(II). The 
coordination geometry for Cu(I) complexes is almost always tetrahedral and remains 
stable in aqueous solution when coordinated to soft donors, such as phosphines and 
thoioethers. The labile nature of most Cu(I) complexes in solution makes them 
unsuitable for radiopharmaceutical applications. The coordination number for Cu(II) 
ranges from 4 to 6 depending on the denticity of the chelator. Four-coordinated Cu(II) 
complexes are normally square planar while 5-coordinated Cu(II) complexes are 
often square pyramidal. The 6-coordinated Cu(II) complexes have a distorted 
octahedral arrangement with the apical donor atoms weakly bound to the Cu(II). 
Jahn-Teller distortion causes axial elongation or tetragonal compression in these 
complexes.17, 18 While Cu(II) complexes are often kinetically labile, they are less 
labile to ligand exchange and are favored for incorporation in radiopharmaceuticals. 
 
Design of Copper-64-labeled Radiopharmaceuticals 
 For target agents with a long biological half-life or those intended for targeted 
radiotherapy, it is imperative that the complexes formed are highly kinetically and 
thermodynamically stable to minimize accumulation of the radiometal in non-target 
tissues. Ligands that form radiocopper complexes with superior kinetic inertness to 
Cu(II) decomplexation are favored over thermodynamic stability because this is more 
significant following injection of the radiopharmaceutical into a living organism. 
Reduction of Cu(II) to Cu(I) followed by Cu(I) loss may be another mode of 
radiocopper loss, so resistance of the complex to Cu(II)/Cu(I) reduction and 
reversibility can also be important. Rapid complexation kinetics are favored to allow 
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for easy formation of the metal-chelator complex. Finally, the design of chelators 
should incorporate available functional groups for covalent linking to targeting 
peptides, proteins, and antibodies. A ligand consisting of a functional group for 
attachment to the targeting moiety and a metal complexing ligand is a bifunctional 
chelator (BFC) (Figure 3).9, 19, 20 
 
 
Figure 3. Schematic of a radiopharmaceutical showing a bifunctional chelator (BFC) 
to complex the radioactive metal ion attached to a targeting moiety, such as a 
peptide. 
 The design of BFCs for copper has focused on macrocyclic chelators that 
form kinetically stable and kinetically inert Cu(II) complexes. Copper(II) complexes of 
linear polyaminopolycarboxylate ligands such as ethylenediaminetetraacetic acid 
(EDTA) and diethylenetriaminepentaacetic acid (DTPA) have been shown to have 
rapid transchelation of the Cu(II) to human serum albumin despite having high 
thermodynamic stability.21, 22 Tetraazamacrocyclic chelators, such as cyclen 
(1,4,7,10-tetraazacyclododecane) and cyclam (1,4,8,11-tetraazacyclotetradecane) as 
well as their derivatives, have been shown to be significantly more stable in vivo.23 
Two N-functionalized derivatives of cyclen and cyclam, 1,4,7,10-
tetraazacyclotetradecane-N,N',N'',N'''-tetraacetic acid (DOTA) and 4,11-
bis(carboxymethyl)-1,4,8,11-tetraazabicyclousehexadecane (TETA) respectively, are 
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commonly used examples (Figure 4).24 These BFCs can be covalently attached to 
the peptide by formation of an amide bond between one carboxylate arm of the 
chelator and the peptide’s N-terminus, leaving three carboxylates for possible 
coordination to the radiometal. Both TETA and DOTA have been attached to 
peptides and proteins for labeling with copper radionuclides. Their kinetic stability in 
vivo is far from ideal, with dissociation leading to higher concentrations of 64Cu in the 
blood and liver, which decreases the efficacy for imaging and therapy.24 
 
 
Figure 4. Structures of tetraazamacrocyclic chelators, and three dimensional 
representations of Cu(II)-DOTA, Cu(II)-TETA, and Cu(II)-CB-TE2A based on crystal 
structures. 
 
Endeavoring to develop more stable BFCs for copper radionuclides, a new 
class of bicyclic tetraamines featuring ethylene cross-bridges has been recently 
reported.25 The radiocopper complex of one such compound, CB-TE2A  
(4,11-bis(carboxymethyl)-1,4,8,11-tetraazabicyclo[6.6.2]hexadecane), demonstrates 
improved blood, liver, and kidney clearance and more favorable biodistribution 
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compared to the standard copper chelates 64Cu-DOTA and 64Cu-TETA.26, 27 
Metabolism studies in rats show that, compared to 64Cu-DOTA and 64Cu-TETA, 64Cu-
CB-TE2A has increased stability and reduced transchelation of 64Cu to liver 
superoxide dismutase (SOD).28 
 Comparison of the structures of the Cu(II) complex of CB-TE2A with DOTA 
and TETA shows distorted octahedral coordination geometry with the copper being 
chelated by four nitrogens and two oxygens for each complex (Figure 4).27 However, 
the coordinating atom arrangement around each Cu(II) is different. Cu(II)-TETA has 
two trans-axial oxygens while the coordinating oxygens for Cu(II)-DOTA and Cu(II)-
CB-TE2A have a cis conformation. Cu(II)-CB-TE2A adopts a low strain conformation 
with all four nitrogen lone pairs coming together in a cleft, allowing the Cu(II) to be 
fully enveloped in a “clamshell” arrangement.27 Both Cu(II)-DOTA and Cu(II)-TETA 
have two non-coordinating carboxylate arms that remain free for potential 
conjugation to a targeting moiety, whereas Cu(II)-CB-TE2A has no free carboxylate 
arms. While this affects the net charge of the cross-bridged macrocyclic complex, it 
has been demonstrated that a single carboxylate arm is sufficient for in vivo stability. 
 Cross-bridged chelators have demonstrated improved kinetic and in vivo 
stability; however, the radiolabeling conditions required for formation of 64Cu-CB-
TE2A and 64Cu-CB-TE2A-peptide conjugates are harsh. Biologically compatible 
aqueous conditions are sufficient for radiocopper complexation by TETA (0.5 M 
NH4OAc, pH 6.5 for 30 min at room temperature (RT)).29 For formation of 
radiocopper cross-bridged chelator complexes, the chelator must be pre-incubated 
for 30 min with excess Cs2CO3 in EtOH at 75º C with constant mixing before the 
addition of 64CuCl2 and then complexation is achieved by heating for 30 min at 75º 
C.30 Cross-bridged chelator-peptide conjugates require somewhat milder labeling 
conditions (0.1 M NH4OAc, pH 6.5 - 8 for 45-90 min at 95º C).31 In order to be 
compatible with larger peptides or antibodies, 64Cu-radiolabeling conditions would 
require aqueous solution near physiological pH at or below 43º C. Thus, 
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development of other kinetically stable and kinetically inert BFCs with favorable 
labeling kinetics remains an active area of research.  
 
Integrin αvβ3 
 Integrins are best understood to constitute an important class of cell adhesion 
receptors. They are responsible for cell-matrix adhesion and signaling across the 
membrane. Integrins and their ligands play key roles in development, immune 
response, leukocyte traffic, hemostasis, cellular entry and exit, and cancer.32 The 18 
known α subunits and 8 known β subunits associate non-covalently to form 24 
integrin heterodimers (Figure 5).33, 34 Each of these appears to have a distinct, non-
redundant function, as concluded from their ligand specificities and from phenotypes 
of knockout mice.35  
 The αvβ3 integrin is expressed on the surface of a variety of cell types 
including endothelial cells,36-39 platelets,40 osteoclasts,41 melanoma,42 and smooth 
muscle.43 Although known as the “vitronectin receptor,” it binds a variety of 
extracellular matrix proteins with the exposed RGD sequences including fibrinogen, 
fibronectin, laminin, collagen, Von WIllibrand’s factor and osteopontin.42 From these 
diverse sites of expression and ligands, it should not be surprising the diversity of 
physiological roles ascribed to it: angiogenesis,44 apoptosis,45 and bone resorption.46 
Induction of angiogenesis by a tumor or cytokine promotes the expression of αvβ3. 
Angiogenesis is essential for the proliferation and metastatic properties of human 
tumors. Unregulated neovasculature is also responsible for a variety of other 
pathological processes such as restenosis,47 rheumatoid arthritis, and retinopothy.48, 
49
 Due to integrin αvβ3’s key role in many physiological processes, it has been 
evaluated extensively as a drug target.50 
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Figure 5. The integrin receptor family. Schematic representation of the mammalian 
subunits and their αβ associations which can be considered in several subfamilies 
based on evolutionary relationships and ligand specificity. RGD receptors are 
indicated on the left-hand side. (Repinted with permission from R.O. Hynes.51) 
 
 The αvβ3 integrin has been targeted with RGD (Arginine-Glycine-Aspartic 
acid) peptides for PET imaging because of its expression on neovasculature as well 
as some tumor cells.52 At least one report demonstrates the ability to image αvβ3 on 
neovasculature in an αvβ3-negative tumor, but other reports indicate that only αvβ3-
positive tumors are detected following injection of a radiolabeled RGD-peptide. 
Neither the mechanism of αvβ3 involvement in tumor neoangiogenesis nor the ability 
to image αvβ3 specifically on blood vessels is well-established. Additionally, 
osteoclasts have high levels of αvβ3 expression where it is required for bone 
resorption. Peptidomimetic αvβ3 antagonists have been found to reduce bone 
resorption in vitro and in vivo. Administration of an αvβ3 antagonist prevented 
hypercalcemia of malignancy in a mouse model of Leydig cell tumor, an effect due to 
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inhibition of tumor cell secretion of osteoclast activating factors or direct inhibition of 
osteoclasts.36 
 
RGD Peptides 
 Proteins that express the RGD attachment sit together with the integrins that 
serve as receptors for them and comprise a major recognition system for cell 
adhesion. Because of its small structure, the RGD site can easily be reproduced with 
peptides. Short peptides containing the basic RGD sequence can mimic cell 
adhesion proteins in two ways. When coated on a surface, they can promote cell 
adhesion, while in solution they block adhesion by serving as decoys. RGD peptides 
that have not been specifically designed to be selective for binding to certain 
integrins mimic a number of adhesion proteins and bind to more than one receptor. 
The peptide can be quite specific in its activity, however. Conformation of the amino 
acids is known to be important; changing the aspartic acid residue to the D-form 
inactivates the peptide. Replacing the aspartic acid with a glutamic acid or the 
glycine residue with an alanine reduces the activity of the peptide in cell attachment 
assays by 100-fold or more. 
 Since the RGD-sequence is conserved in all native ligands, differences in 
binding affinities and specificity can be obtained from slight modifications. The 
flanking amino acid residues, especially the two positions following the aspartic acid, 
are known to change binding affinity both by direct interaction of the residues with 
the integrin as well as influencing peptide folding. Cyclization is a common technique 
to improve binding properties because it confers rigidity on the structure. All selective 
RGD peptides have at least one ring structure. Linear RGD peptides are highly 
susceptible to degradation, due to reaction of the aspartic acid residue with the 
peptide backbone. Non-natural peptide modifications, such as the introduction of D-
amino acids and replacement with peptidomimetic structures, have yielded RGD 
peptide ligands with greater specificity and nanomolar or higher affinities. Multivalent 
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RGD-protein conjugates demonstrate subnanomolar affinity for αvβ3-expressing 
human umbilical vein endothelial cells (HUVEC), a 250-fold increase verses the 
monomer. Furthermore, multivalency has been shown to facilitate internalization. 
Carrier systems like liposomes, nanoparticles, and proteins bearing multiple RGD 
peptides are therefore more likely to be internalized via receptor-mediated 
endocytosis than single peptide constructs. 
 
Nanotechnology 
 Nanotechnology is a rapidly expanding field, benefiting from multidisciplinary 
efforts in research, development, and education. It is a broad field encompassing 
everything from nanoscale phenomena and processes to societal studies of the 
benefits and risks of nanotechnology. Conventionally, nanoscale materials are 
defined as being man-made and having a size of 1 to 100 nm in at least one 
dimension. Unusual physical, chemical, and biological properties can emerge in 
materials at the nanoscale. These properties may differ in important ways from the 
properties of bulk materials and single atoms or molecules. The size of nanoparticles 
makes them capable of imitating many features of biological species, including 
proteins, a feature being taken advantage of by scientists to probe cell structure and 
function at the sub-cellular level. Advances in nanotechnology and medicine in the 
past decade are allowing researchers to take advantage of many unique properties 
of nanoscale materials for improved diagnosis and treatment of disease. 
 Nanomedicine is the application of nanotechnology to disease treatment, 
diagnosis, monitoring and control of biological systems, as defined by the National 
Institutes of Health (NIH). The goal of nanomedicine is to develop safer and more 
effective therapeutic and diagnostic modalities. Because of the size and 
supramolecular structure of nanoparticles, technologies utilizing nanoparticles have 
much potential for improving cancer therapy. A primary attribute of nanoparticle 
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delivery systems is their potential to enhance the tumor accumulation of anticancer 
agents in tumor cells than healthy tissues.  
 Polymeric nanoparticles have attracted interest for their potential applications 
in nanomedicine. Shell crosslinked nanoparticles (SCKs) mimic the amphiphilic core-
shell morphology with a hydrophobic core contained within a hydrogel network. They 
are prepared from self-assembly of amphiphilic block copolymers which are 
subsequently crosslinked between the polymer chains located within a shell. SCKs 
present many available sites for surface functionalization by attachment of a variety 
of compounds, such as receptor-targeting ligands, cell penetrating peptides, and 
chelators for radiolabeling. Guest molecules can be encapsulated by the hollowing of 
the core by selective degradation of the polymer chains.  The properties of SCKs are 
tunable by control of size, shape, and particle composition, as has been 
demonstrated previously by Murthy et al.52 
 Through a multidisciplinary collaboration between physicians and scientists at 
Washington University, a concerted effort is underway to develop a group of well-
characterized and versatile nanoscale agents for targeted drug delivery. Novel SCKs 
with the peptide KCRGDC have been evaluated for their affinity for the αvβ3 integrin.  
 
Summary of Research 
 Molecular imaging plays an increasingly important role in disease 
management, from screening and diagnosis to treatment and follow-up. This is 
dependent upon the development of robust and specific image contrast agents. The 
goal of this dissertation is to develop novel radiometal-based radiopharmaceuticals 
for medical imaging. This has been addressed from the perspective of both the 
bifunctional chelators as well as the targeting moiety. 
 Stability of metal chelates in vivo is a considerable challenge but 
consideration must also be paid to the complex formation kinetics. In this work, 
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several macrocyclic copper(II) chelators have been studied with the goal of 
developing a BFC with good complex formation kinetics and in vivo stability. 
 Integrin αvβ3 is implicated in many disease processes—angiogenesis, 
proliferation of vascular smooth muscle following injury, tumor metastasis, 
inflammation, and osteolysis. With so many potential disease targets, it is an 
interesting molecular target for diagnostic and therapeutic imaging. This work reports 
on the investigation of structurally diverse bifunctional RGD peptides for affinity for 
integrin αvβ3 in vitro and in vivo. In vitro characterization of RGD-functionalized 
nanoparticles is also presented. 
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CHAPTER 2 
 
Preparation and In Vivo Investigation of 64Cu-Labeled Cross-Bridged  
Tetrazamacrocyclic Complexes, C3B-DO2A and CB-TR2A: Comparison with NOTA 
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Abstract 
Copper radionuclides have been the subject of considerable research effort 
because they offer a varying range of half-lives and positron energies, making them 
useful for diagnostic imaging and/or targeted radiotherapy. Ensuring the stability of 
metal complexes in vivo remains a challenge in the development of radiometal-
based radiopharmaceuticals. A new class of structurally reinforced macrocycles, 
“cross-bridged” cyclam derivatives, form highly stable complexes with Cu(II) that are 
resistant to dissociation in strong acid and have rapid tissue clearance in 
biodistribution studies; however, their radiolabeling is inefficient and requires harsh 
conditions that are unsuitable for larger biomolecules. Here, we report the evaluation 
of three macrocyclic chelators--C3B-DO2A, CB-TR2A, and NOTA—as we seek more 
rapid Cu(II) complexation kinetics while retaining the high in vivo stability of CB-
TE2A. The natCu complexes were characterized by structure evaluation, inertness to 
acid decomplexation, and electrochemical properties. The inertness of Cu-C3B-
DO2A to decomplexation is remarkable, exceeding that of CB-TE2A. 
Electrochemical reduction of Cu-CB-TR2A is quasi-reversible; Cu-C3B-DO2A and 
Cu-NOTA are irreversible. The reaction conditions for preparing 64Cu-C3B-DO2A 
(microwaving at high temperature) and 64Cu-CB-TR2A (basic ethanol) are relatively 
harsh compared to those for the conventional complexes, such as DOTA. The in vivo 
behavior of 64Cu-ligand complexes was evaluated in normal rats. Rapid and continual 
clearance of 64Cu-CB-TR2A and 64Cu-NOTA through the blood, liver, and kidneys 
suggests good in vivo stability, although inferior to 64Cu-CB-TE2A. Although 64Cu-
C3B-DO2A clears continually, the initial uptake is high and only about half is 
excreted within 22 h, suggesting poor stability and transchelation of 64Cu to proteins 
in the blood and/or liver. These data suggest that in vitro stability of a chelator may 
not always be a good indicator of in vivo stability. Furthermore, a macrocyclic 
chelator with rapid complexation kinetics which also demonstrates kinetic inertness 
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comparable to the previously studied 64Cu-CB-TE2A, under physiological conditions, 
has not yet been identified. 
 
Introduction 
Radiopharmaceuticals, drugs containing a radionuclide, are routinely used in 
nuclear medicine for the diagnosis and therapy of various diseases.9, 53-55 An ideal 
radiopharmaceutical would be injected intravenously, travel via the blood stream to 
the target tissue or cells, and interact in an effective manner and with only the 
desired molecular pathway.56 Excretion of any radiopharmaceutical that did not reach 
the intended target would occur rapidly, leaving in the body only the fraction of the 
radiotracer which localized to the target site. While an ideal compound may never 
exist, the objective in radiopharmaceutical design is to come as close as possible.  
 Substrate-specific radiopharmaceuticals are designed to target a specific 
biological process, protein, or receptor expressed in distinct regions of the body. 
Generally, a substrate-specific metalloradiopharmaceutical is composed of four 
parts: a targeting biomolecule, a linker, a bifunctional chelator (BFC), and a metallic 
radionuclide (Figure 1).18, 57 Each of these components must be considered in light of 
each other and optimized as a whole. Thus, the design of novel BFCs and their 
characterization with specific radiometals is an area of ongoing research.  
 BFCs must form a very stable metal chelate, demonstrating kinetic inertness 
at physiological pH. Its solution stability in biological medium depends primarily on a 
slow rate of dissociation. This is important to avoid a loss of radiometal from the 
chelate, resulting in the accumulation of radioactivity in non-target tissue that 
obscures imaging of the desired target and increases the radiation dose the subject 
receives. Rapid complexation kinetics are also favored to allow for easy formation of 
the metal-chelator complex. 
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Figure 1. Conceptual diagram of a substrate specific metalloradiopharmaceutical. 
 
 As discussed in the introduction (chapter 1), copper radionuclides have been 
the subject of considerable research effort because they offer a varying range of half-
lives and positron energies, making them useful for diagnostic imaging and/or 
targeted radiotherapy. Their half-lives range from 10 minutes to 62 hours, and they 
decay by positron (β+) and/or beta-minus (β-) emission. The biodistribution of these 
copper radionuclides can be assessed externally via clinical positron or gamma 
imaging techniques. Copper-64 has a long history of applications as a biomedical 
tracer because of its longer half-life and short positron range (T1/2=12.7 h; β+: 0.656 
MeV, 17.8%; β-: 0.573 MeV, 38.45%).58 
 Kinetic stability of Cu(II) complexes has been shown to be more predictive of 
in vivo stability than thermodynamic stability.22, 59 Since the coordination chemistry of 
copper radionuclides has been extensively reviewed,15, 57 only a brief summary will 
be given here. Macrocyclic chelators of Cu(II) such as TETA (1,4,8,11-
tetraazacyclotetradecane-1,4,8,11-tetraacetic acid) demonstrate higher kinetic and 
thus in vivo stability relative to acyclic chelators such as EDTA (ethylene diamine 
tetraacetic acid).12, 59, 60 However, biodistribution and metabolism studies of 64Cu-
TETA in rats have demonstrated significant transchelation of 64Cu to superoxide 
dismutase and metallothionein in liver and albumin in blood resulting in high 
background radioactivity.61, 62 Cu(II) complexes with a class of chelators called the 
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cross-bridged macrocycles, in particular CB-TE2A (4,11-bis(carboxymethyl)-
1,4,8,11-tetraazabicyclo[6.6.2]hexadecane), have shown much greater in vivo 
stability;62, 63 however, a disadvantage of CB-TE2A is that labeling with copper 
radionuclides requires heating to 95 ºC, and this precludes the use of this chelator 
with proteins or other heat-sensitive compounds. 
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Figure 2. Structures of representative polyamine and polyaminocarboxylate acyclic 
and cyclic chelators for radiometal complexation. 
 
 To design cross-bridged chelators that complex Cu(II) with faster kinetics 
while retaining the high in vivo stability of CB-TE2A, different ring sizes of cross-
bridged tetraazamacrocycles were designed. First, a dicarboxylate analog of 
Springborg’s trimethylene-cross-bridged cyclen64, 65 was proposed. This DOTA 
analog, 4,10-bis-(carboxymethyl)-1,4,7,10-tetrazazabicyclo[5.5.3]pentadecane  
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(C3B-DO2A), has one more methylene unit in the cross-bridge than the previously 
studied CB-DO2A.62 The biodistribution of 64Cu-CB-DO2A demonstrated rapid 
clearance of the agent through the blood, liver, and kidneys. It is hypothesized that 
the increased ring size of C3B-DO2A will improve the radiolabeling kinetics while 
retaining the in vivo stability of CB-DO2A.  
 Homocyclen has a ring size falling between that of cyclen and cyclam. Just 
as C3B-DO2A was chosen for its slightly larger ring size than the previously studied 
CB-DO2A, a two-carbon cross-bridged dicarboxylate analog of homocyclen, 4,11-
bis-(carboxymethyl)-(1,4,8,11-tetraazabicyclo[6.5.2]pentadecane (CB-TR2A), was 
proposed.  
 Prasanphanich et al. recently reported 64Cu-labeled bombesin analogs using 
1,4,7-triazacyclononane-N,N’,N’’-triacetic acid (NOTA) as a chelator. The reduced 
liver and intestinal accumulation suggested high in vivo kinetic stability of 64Cu-
NOTA-bombesin vectors with little or no dissociation of 64Cu from NOTA.66 This 
chelator has been used multiple times as a BFC for 64/67Cu and 68Ga attachment to 
antibodies67 and peptides68, 69; however, an evaluation of the in vivo stability of the 
64Cu-NOTA complex has not previously been reported. Stability constants for several 
metal-NOTA complexes are found in literature70, 71 as well as crystal structures for 
Cu(II)-NOTA and Ga(III)-NOTA.72, 73 NOTA deviates from most of the macrocyclic 
chelators that we investigate because it is a triazamacrocycle and not cross-bridged; 
however, its reported high in vivo stability and rapid labeling kinetics drive our 
interest in this molecule. 
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Figure 3. Structures of cross-bridged tetraazamacrocyclic chelators, C3B-DO2A and 
CB-TR2A, as well as triazamacrocyclic chelator, NOTA. 
 
Here we present the results of our efforts to develop kinetically stable cross-
bridged azamacrocycles. We synthesized a three-carbon cross-bridged DO2A, 4,10-
bis-(carboxymethyl)-1,4,7,10-tetrazazabicyclo[5.5.3]pentadecane (C3B-DO2A), and 
a two-carbon cross-bridged TR2A, 4,11-bis-(carboxymethyl)-(1,4,8,11-
tetraazabicyclo[6.5.2]pentadecane (CB-TR2A). These novel BFCs were investigated 
for their potential use in constructing new PET imaging agents with improved 
properties. Copper(II) complexes were synthesized and characterized by structure, 
acid decomplexation and electrochemistry. Optimized 64Cu-radiolabeling conditions 
were established for each chelator. The biodistribution of 64Cu-C3B-DO2A and 64Cu-
CB-TR2A in normal rats was compared to another highly stable macrocyclic chelator 
that has been used to complex 64Cu to biological molecules, 1,4,7-
triazacyclononane-N,N’,N’’-triacetic acid (NOTA). 
 
Experimental Procedures 
 Materials and methods. Unless otherwise specified all chemicals were 
purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO) and used as received. 
All solutions were prepared using water which had been distilled and then deionized 
(18 MΩ/cm2) by passing through a Milli-Q water filtration system (Millipore Corp., 
Bedford, MA). Trace metals were removed from all buffers used for radiolabeling by 
Chelex 100 resin (BioRad Laboratories, Hercules, CA). Whatman C18 silica gel TLC 
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plates (KC18F, 60 Å, 200 µm) were purchased from Fisher Scientific (Pittsburgh, 
PA). Copper-64 was prepared on a biomedical cyclotron at Washington University 
Medical School by the 64Ni(p,n)64Cu nuclear reaction at high specific activity as 
previously described.74 Male Lewis rats were purchased from Charles River 
Laboratories (Boston, MA). 
 Radio-TLC was accomplished using a Bioscan 200 imaging scanner 
(Bioscan, Inc., Washington, DC). Analytical reversed-phase HPLC was performed on 
a Waters 600E (Milford, MA) chromatography system with a Waters 991 photodiode 
array detector and an Ortec Model 661 radioactivity detector (EG&G Instruments, 
Oak Ridge, TN). Radioactive samples were counted with a Beckman 8000 
automated well-type gamma counter (Beckman Instruments, Inc., Fullerton, CA) or a 
Wallac Wizard 1480 automatic gamma counter (Perkin Elmer, Gaithersburg, MD).  
 Optimization of radiolabeling conditions for preparation of 64Cu-C3B-
DO2A. A solution of C3B-DO2A (1 µg/µL) was prepared by dissolving the ligand in 
0.1 M ammonium acetate, pH 7.0, or ethanol. Except for microwave assisted 
reaction, all reactions were carried out in 1.5 mL acid washed conical vials and 
shaken for the duration of the incubation. A variety of aqueous reaction conditions 
were tested, with incubation times, ligand concentrations, buffer concentration and 
pH, temperatures, and radiochemical yields reported in the results section (Tables 2-
6). The method for radiolabeling described by Boswell et al. for the synthesis of 64Cu-
CB-TE2A62, and described below for the production of 64Cu-CB-TR2A, was tested for 
formation of 64Cu-C3B-DO2A (Tables 7-8). At several time points, the outcome of the 
labeling experiment was assessed by radio-TLC (Rf ~ 0.8, C18 silica plates, eluent: 
methanol/10% ammonium acetate 7:3, Rf (64Cu-acetate = 0). Radio-TLC results for 
some reactions were confirmed by radio-HPLC (Agilent C8 column; isocratic, 0.1% 
formic acid in water; 0.5 mL/min). When radiolytic stabilizers were used, a final 
concentration of 1 mM gentisic acid (GA) or ascorbic acid (AA) was added prior to 
incubation. For carrier-added reactions, a 100 mM solution of CuCl2 in milliQ water or 
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absolute EtOH was added to the ligand solution prior to addition of the 64CuCl2. 
Microwave assisted reactions were carried out using a Biotage Initiator closed vessel 
reactor (Biotage AB, Uppsala, Sweden). Solvent, pH, temperature, and length of 
reaction were varied to find conditions that resulted in consistent radiochemical purity 
of ≥ 98% (Table 9).  
 The highest radiochemical purity with greatest consistency of yield was 
obtained using a microwave assisted reaction. A solution of 64CuCl2 (750 µCi in 50 
µL milliQ water, pH 3) was added to 4.61 µg (14.0 nmol) C3B-DO2A dissolved in 250 
µL of milliQ water (pH 3). The sealed vial containing the reaction mixture was placed 
in the microwave reactor, stirred for two minutes, and then heated at 100 °C for 2 h. 
Complex formation was confirmed by radio-TLC. Radiochemical purity was 
determined by HPLC and found to be ≥ 98% before use in animal studies. 
 Preparation of 64Cu-NOTA. An aqueous solution of 64CuCl2 (1.3 mCi, 50 µL, 
0.1 M NH4OAc, pH 7.0) was added to 4.17 µg (13.7 nmol) of NOTA dissolved in 50 
µL of 0.1 M NH4OAc, pH 7.0. The reaction mixture was incubated with shaking at 37 
°C for 1 h. Complex formation was followed by radio- TLC (Rf ~ 0.75, C18 silica 
plates, eluent: methanol/10% ammonium acetate 7:3, Rf (64Cu-acetate = 0). 
Radiochemical purity of  
≥ 98% was attained. 
 Biodistribution Studies. Animal experiments were carried out in compliance 
with the Guidelines for the Care and Use of Research Animals established by 
Washington University’s Animal Studies Committee. Tissue distribution studies were 
performed in male Lewis rats (34-42 day old) after intravenous injection of the 
radiolabeled compound, 64Cu-C3B-DO2A (45 µCi; 0.9 nmol ligand), 64Cu-CB-TR2A 
(100 µCi), or 64Cu-NOTA (60 µCi; 0.5 nmol ligand), via the tail vein (100-150 µL). 
Tissue biodistribution data were obtained at 1, 4, and 24 hours post injection (PI). 
Animals were sacrificed at the appropriate time points, organs of interest were 
removed and weighed, and the radioactivity was measured in a gamma counter. The 
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percent injected dose per gram (%ID/g) and percent injected dose per organ 
(%ID/organ) were calculated by comparison to a weighed and counted standard. 
Rats were allowed food and water ad libitum. Animals in the 24 h group for 64Cu-
C3B-DO2A and 64Cu-NOTA were maintained in metabolism cages; urine and feces 
were collected. 
 Statistical methods. All data are presented as the mean ± standard 
deviation. Group comparisons were made using standard ANOVA methods. Post hoc 
testing of individual group differences was accomplished with the Bonferroni test. 
Groups with p < 0.05 were considered significantly different. GraphPad Prism 
software (version 5.02; San Diego, CA) was used for all statistical analyses. 
 Collaborators. The experimental procedures for work performed by 
collaborators are included as supplemental material Appendix I. Synthesis of C3B-
DO2A was performed by Dr. Riccardo Ferdani, CB-TR2A by Yijie Peng (University of 
New Hampshire, Durham, NH)75 and NOTA by Elizabeth Garcia (UNH). Synthesis of 
all natCu(II)-chelator complexes and their characterization was carried out at UNH in 
the laboratory of Dr. Ed Wong. The Cu-CB-TR2A work has been reported in the 
doctoral dissertation of Antoinette Odeendaal (UNH).76 X-ray crystallography was 
done in the laboratory of Dr. Arnold Rheingold at the University of California—San 
Diego (La Jolla, CA); Cu-CB-TR2A structure solved by James Golen. Dr. Thad 
Wadas was responsible for radiochemistry involving CB-TR2A. 
 
Results 
 Synthesis of Ligands. The synthesis and characterization of the chelator 
and Cu(II) complex of the cyclen-based cross-bridged chelator, C3B-DO2A, and that 
of the homocyclen-based cross-bridged chelator, CB-TR2A, have not previously 
been reported. The low overall yield for the synthesis of C3B-DO2A (18%) was 
primarily due to the cross-bridging step which had a yield of 21%. The compound 
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has subsequently been synthesized by a different synthetic route in much higher 
yield. 
Cu-C3B-DO2A. The complexation of Cu(II) by the ligand was relatively slow, 
requiring overnight reflux in 95% ethanol solution. It was found subsequently that 
under microwave irradiation, the complex can be more conveniently formed in 
aqueous solution at 85° after 1 h at pH 6. The comple x co-crystallized with NaClO4 
as well as with waters of hydration. The solution electronic spectrum showed a 
visible maximum at 614 nm, typical of Cu(II)-cross-bridged complexes. Solid-state 
FT-IR spectrum revealed carboxylate bands at 1687 (m, s) and 1616 (s, bd) cm-1. An 
X-ray structural determination of crystals grown from hexafluoro-i-propanol revealed 
a distorted octahedral geometry with Jahn-Teller elongation along one N-Cu-O axis 
(Figure 4). The cation is only slightly distended from the chelator cavity with an 
“axial” N-Cu-N angle of 173.6° and “equatorial” N-C u-N angle of 97.5°. 
The inertness of Cu-C3B-DO2A (half-life = 7.2(7) days) to decomplexation in 
12M HCl at 90 °C, even exceeding that of the Cu-CB-T E2A (half-life = 1.3(2) h)57, is 
remarkable. This attests to the optimal envelopment of the Cu(II) within the ligand’s 
hexadentate coordination sphere. To begin the demetallation process, dislodgement 
of at least one pendant arm and rupture of a Cu-N bond must be followed by major 
chelator structural rearrangements. The kinetic barrier to such an event must be 
significantly higher even than that for Cu-CB-TE2A, previously the most acid-inert 
Cu(II)-tetraazamacrocyclic complex. 
Similar inertness is not observed upon electrochemical reduction as revealed 
by the cyclic voltammogram of this complex. An irreversible reduction was found 
near -1.0 V (Ag/AgCl) with no reoxidation peak until the large stripping peak near 0 
V, indicative of copper metal deposition. Thus Cu(I)-C3B-DO2A, if formed, must have 
low stability in aqueous solution and is thus rapidly demetallated.  
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Figure 4. Structures of Cu-C3B-DO2A and Cu-CB-TR2A (Complex A) based on 
crystallographic data. For clarity, all hydrogens are omitted. 
Cu-CB-TR2A. The complexation of Cu(II) by the ligand CB-TR2A was 
accomplished following overnight reflux in 95% ethanol solution. Elemental analysis 
of Cu-CB-TR2A was consistent with a composition of Cu•CB-
TR2A•1.2Na(ClO4)•2H2O. Two strong broad IR bands were observed, one at 1610 
cm-1, which corresponds to the carboxylate stretching vibration, and another at 1098 
cm-1, which corresponds to the perchlorate stretching vibration. The UV-Vis spectrum 
in H2O has an absorption λmax at 608 nm (ε = 32.1 M-1cm-1).  
 An X-ray crystal structure determination of Cu•CB-TR2A was obtained after a 
second slow Et2O diffusion into a solution of complex in 95% EtOH. The structure 
showed the presence of three unique cis-V-folded complexes each with a six-
coordinated distorted octahedral copper, but each with a different ligand 
conformation (Complex A shown in Figure 4). Jahn-Teller elongated bonds were 
observed for each complex along one N-Cu-O axis. The metal center is only slightly 
distended from the chelator cavity as indicated by the “axial” N-Cu-N bond angles 
(Complex A: “axial” N-Cu-N 176.8(2)o; Complex B: 168.7(2)o).  
 The acid-decomplexation half-life of Cu-CB-TR2A was determined to be 
10.8(4) h in 5 M HCl at 30 oC, conducted under pseudo-first order conditions. This is 
between the half-lives of Cu-CB-DO2A and Cu-CB-TE2A (Table 1). Although not as 
32 
 
kinetically inert as Cu-CB-TE2A, Cu-CB-TR2A is significantly more resistant to acid 
decomplexation than Cu-CB-DO2A whose ligand cavity is smaller. The cyclic 
voltammogram of Cu-CB-TR2A has a quasi-reversible reduction at -0.95 V (vs. 
Ag/AgCl) with a peak separation of 138 mV. This is between the values found for Cu-
CB-TE2A and Cu-CB-DO2A (Table 1) and indicates that Cu-CB-TR2A is more 
resistant to reductive demetallation than Cu-CB-DO2A, though not as resistant as 
Cu-CB-TE2A. Quasi-reversible reduction suggests that the chelator can adapt a 
geometry suitable for Cu(I) coordination.77 
 
Table 1. Pseudo first-order half-lives for acid-decomplexation and  
reduction potentials of copper(II) complexes. 
Complex 12 M HCl, 90°C 
5 M HCl, 
90°C 
5 M HCl, 
30°C 
Ered (V) vs. 
Ag/AgCl 
Overall 
Charge 
Cu-C3B-DO2A 7.2(7) days nd nd -1.03 (irrev)   0 
Cu-CB-DO2Ab nd nd < 2 min -0.85 (irrev)   0 
Cu-DOTA < 3 mina nd nd -0.94 (irrev)c -2 
Cu-CB-TR2A nd nd 10.8(4) h 
-0.95 (quasi-
rev, ∆E=138 
mV) 
  0 
Cu-CB-TE2Aa 1.6(2) h 154(6) h > 1 year 
-1.08 (quasi-
rev, ∆E=120 
mV) 
  0 
Cu-TETAb < 3 min 4.5(5) min 3.5(2) days -1.18 (irrev) +2 
Cu-cyclama < 3 min < 3 min nd -0.68 (quasi-
rev) +2 
Cu-NOTA nd nd < 3 min -0.9, -1.2 (irrev) -1 
Previously published data: a=Wadas et al.57; b=Woodin et al.77; c=Boswell et al.62 
 
Cu-NOTA. The acid inertness of this complex in 1M HCl at 30 °C is superior 
to that of Cu-cyclen, Cu-TACN, and Cu-CB-DO2A, all of which were completely 
decomplexed after 1 day. It is, however, demetallated within minutes in 5 M HCl at  
30 °C, making it considerably less inert than Cu-DOTA, Cu-TETA, as well as Cu-CB-
TR2A (Table 1). Among the chelators shown here, Cu-C3B-DO2A is the most 
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kinetically inert and Cu-NOTA one of the least. The relative order is Cu-C3B-DO2A > 
CB-TE2A >> Cu-TETA ≈ Cu-DOTA > Cu-CB-TR2A > Cu-CB-DO2A ≈ Cu-NOTA. 
While they only provide a qualitative estimate of comparative kinetic inertness, the 
resistance of a copper chelate complex to aqueous acid decomplexation generally 
serves as a useful first indicator of the likely in vivo integrity of the complex towards 
metal loss due to protonation, competing biometals, or biological ligands.78 
The cyclic voltammogram contained two irreversible reduction peaks at -0.9 
and -1.2 V (Ag/AgCl) along with the large copper stripping peak upon reoxidation. 
Thus Cu(I)-NOTA does not appear to be a stable species in aqueous solution. 
Comparison to other chelators is provided in Table 1. A threshold potential of 
approximately -1 V with quasi-reversibility is generally indicative of good in vivo 
stability. 
 Radiochemistry. Optimization of the radiolabeling conditions for 64Cu-C3B-
DO2A to be compatible with the conjugation and labeling of proteins (i.e. lower 
temperature) was not attained. Radiolabeling was attempted under a variety of 
aqueous conditions varying the buffer, pH, and temperature. The reaction conditions 
and 64Cu-labeling yields for numerous attempts to attain rapid kinetics in aqueous 
ammonium acetate (NH4OAc) are presented in Tables 2-4. For reaction conditions 
repeated multiple times, the highest yield is reported in each series. 
 Phosphate and citrate buffers resulted in similarly inconsistent and 
disappointing yields (Table 5). Reactions were monitored over time to assess the 
rate of complexation. Instability of the 64Cu-C3B-DO2A complex was observed in the 
form of secondary peak formation and yields which peaked and then declined. 
Although radiolysis is not commonly observed for small molecules, reactions were 
carried out in the presence of two different radiolytic scavengers (Table 6). Carrier-
added reactions did not produce any improvement in radiolabeling. 
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Table 2. Initial radiolabeling attempts for 64Cu-C3B-DO2A. In all reactions  
0.5 µg C3B-DO2A was incubated with 100 µCi 64Cu in a total volume of 50 µL. 
    Yield (%) 
Buffer Concentration pH 
Temp 
(°C) 30 m 7 h 
NH4OAc 0.1 M 8.0 25 6 9 
NH4OAc 0.5 M 6.0 25 6 28 
NH4OAc 0.5 M 8.0 25 23 52 
NH4OAc 1.0 M 7.0 25 4 22 
NH4OAc 1.25 M 4.5 25 1 3 
NH4OAc 0.1 M 8.0 37 3 9 
NH4OAc 0.5 M 6.0 37 11 9 
NH4OAc 0.5 M 8.0 37 23 12 
NH4OAc 1.0 M 7.0 37 1 10 
NH4OAc 1.25 M 4.5 37 1 2 
 
 
Table 3. Secondary radiolabeling attempts for 64Cu-C3B-DO2A. In all reactions  
1.0 µg C3B-DO2A was incubated with 100 µCi 64Cu in 0.1 M NH4OAc (50 µL). 
  Yield (%) 
pH Temp (°C)  1.5 h 3.5 h 18 h 
6.0 25 47 45 32 
7.0 25 27 46 82 
8.0 25 72 45 40 
6.0 95 30 58 90 
7.0 95 19 19 35 
8.0 95 34 50 90 
 
 
Table 4. Further radiolabeling attempts for 64Cu-C3B-DO2A. In all reactions  
1.0 µg C3B-DO2A was incubated with 150 µCi 64Cu in 0.1 M NH4OAc (50 µL). 
  Yield (%) 
pH 
Temp 
(°C) 
1 h 6 h 
8 h 18 h 
8 25 6 8 14 54 
8.5 25 8 31 43 21 
9 25 11 36 56 41 
8 40 4 22 7 39 
8.5 40 40 12 10 32 
9 40 69 5 83 13 
8 95 27 53 49 46 
8.5 95 26 49 37 68 
9 95 21 53 66 79 
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Table 5. Alternate buffers used for attempted radiolabeling of 64Cu-C3B-DO2A.  
In all reactions 0.5 µg C3B-DO2A was incubated with 70 µCi 64Cu in a total  
volume of 50 µL at 95 °C. 
   Yield (%) 
Buffer Concentration pH 1 h 4 h 
NH4Citrate 0.1 M 5.5 21 23 
NH4Citrate 0.1 M 7.0 31 30 
NH4Citrate 0.1 M 8.0 64 58 
NH4Citrate 0.5 M 7.0 28 39 
Na2PO4 0.1 M 5.5 34 18 
Na2PO4 0.1 M 7.0 22 55 
Na2PO4 0.5 M 7.5 27 51 
 
 
Table 6. Radiolabeling attempts for 64Cu-C3B-DO2A with radiolytic  
scavengers. In all reactions 1.0 µg C3B-DO2A was incubated with  
100 µCi 64Cu in 0.1 M NH4OAc (50 µL) at 95 °C. 
  Yield (%) 
pH Scavenger 1 h 4 h 16 h 
5.5 GA 7 20 33 
7 GA 8 45 64 
8.5 GA 21 34 61 
5.5 AA 5 11 22 
7 AA 17 45 42 
8.5 AA 32 36 62 
 
 
 After such exhaustive attempts at radiolabeling under aqueous conditions, 
the standard CB-TE2A radiolabeling conditions79 were attempted (Tables 7-8). Table 
7 includes data on a radiolabeling attempt using Li2CO3 as the base instead of 
Cs2CO3. The effect of specific activity was assessed showing limited improvement in 
radiochemical yield (Table 8). Again, carrier-added reactions did not generate any 
improvement in radiolabeling yield. 
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Table 7. Radiolabeling 64Cu-C3B-DO2A in ethanol with excess base.  
In all reactions 0.5 µg C3B-DO2A was incubated with 100 µCi 64Cu. 
 Yield (%) 
Time Cs2CO3; 100 µL Cs2CO3; 50 µL Li2CO3; 100 µL 
1 h 43 70 3 
3 h 60 43 5 
4.5 h 70 nd 4 
6 h 65 nd 3 
18 h
 
35 nd 6 
 
 
Table 8. Radiolabeling 64Cu-C3B-DO2A in ethanol with excess Cs2CO3.  
In all reactions C3B-DO2A was incubated with 130 µCi 64Cu in a total volume of 80 
µL. 
 Yield (%) 
Time 1 µg C3B-DO2A 2 µg C3B-DO2A 
3 µg C3B-
DO2A 
1 h 32 64 64 
2.5 h 37 67 85 
4 h 32 63 83 
6 h 20 47 nd 
18 h
 
30 66 74 
 
 
 In an attempt to speed up the reaction kinetics, the use of a microwave 
reactor was employed (Table 9). While reaction times can be shortened due to the 
concentrated heating of a microwave reactor, the sealed vial system limited the 
number of time points assessed for each set of reaction conditions. Shorter reaction 
times did not initially produce high yields, so longer reaction times were utilized until 
higher yields were attained. Then reaction length optimization occurred, finding the 
shortest reaction time required to consistently provide a minimum of 97% 
radiochemical purity. 
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Table 9. Microwave assisted radiolabeling 64Cu-C3B-DO2A. In all reactions 1.0 µg 
C3B-DO2A was incubated with ~100 µCi 64Cu in a total volume of 300 µL. 
Solvent pH Temp (°C) Time Yield (%) 
0.1 M NH4OAc 7 60 1 h 9 
0.1 M NH4OAc 7 60 4 h 30 
0.1 M NH4OAc 7 95 1 h 38 
0.1 M NH4OAc 7 95 4 h 50 
0.1 M NH4OAc 7 95 6 h 28 
0.5 M NH4OAc 7 60 1 h 38 
0.5 M NH4OAc 7 85 4 h 44 
0.5 M NH4OAc 7 95 1h 39 
0.5 M NH4OAc 7 95 4 h 55 
0.1 M NH4OAc 5 95 4 h 61 
0.1 M NH4OAc 8.5 95 4 h 82 
0.1 M NH4OAc 8.5 150 4 h 48 
0.1 M NH4OAc 8.5 180 4 h 45 
0.1 M Na2PO4 7 60 4 h 39 
0.1 M Na2PO4 7 95 4 h 59 
0.5 M Na2PO4 7.5 95 4 h 52 
milliQ water 3 95 4 h 87 
milliQ water 3 100 4 h 99 
milliQ water 3 100 1h 91 
milliQ water 6 95 4 h 83 
milliQ water 6 100 4 h 94 
milliQ water 6 100 1h 85 
milliQ water 3 100 2h 99 
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 CB-TR2A was successfully labeled with 64Cu by the method employed for 
CB-TE2A and other cross-bridged chelators24, 79 (radiochemical purity ≥ 98%) at 
room temperature in basic ethanolic solution. A single peak corresponding to 64Cu-
CB-TR2A was confirmed by radio-TLC. 
 The NOTA chelator used for comparison was successfully labeled with 64Cu 
at room temperature in neutral buffer solution, with radiochemical purity ≥ 98% 
attainable within one hour. A single peak corresponding to 64Cu-NOTA was verified 
by radio-TLC. 
 Biodistribution Studies. The biodistribution of 64Cu-C3B-DO2A, 64Cu-CB-
TR2A, and 64Cu-NOTA were determined in normal, juvenile Lewis rats to examine 
their in vivo properties. The blood, liver, and kidney clearance of these agents are 
plotted in Figure 5 along with previously published data of 64Cu-CB-DO2A62 and 
64Cu-CB-TE2A63 for comparison. For 64Cu-CB-TR2A and 64Cu-NOTA rapid clearance 
of the agent through the blood, liver, and kidneys was observed, suggesting that the 
intact complex is clearing because dissociated 64Cu binds to proteins and remains 
trapped in tissues, hindering clearance.61 Comparable levels of clearance are 
observed for blood (%ID/g at 24 h PI: 64Cu-CB-TR2A, 0.010±0.002; 64Cu-NOTA, 
0.016±0.001) and liver (%ID/g at 24 h PI: 64Cu-CB-TR2A, 0.075±0.014; 64Cu-NOTA, 
0.086±0.009). The highest uptake in all organs is observed for 64Cu-C3B-DO2A at all 
time points. Clearance of 64Cu-C3B-DO2A is slow but continuous (from 1h to 22 h: 
blood 29.8% reduction; liver 22.2%; kidney 50.4%). All other compounds have higher 
percent reduction for all three organs than 64Cu-C3B-DO2A. The rate of clearance 
from liver is higher for cyclam-based cross bridged chelators and lower for non-
cross-bridged NOTA (percent reduction at 22 or 24 h PI: 64Cu-CB-TR2A, 66.4%; 
64Cu-NOTA, 46.3%; 64Cu-C3B-DO2A, 22.2%; 64Cu-CB-DO2A, 69.5%; 64Cu-CB-
TE2A, 90.2%). Kidney uptake cleared by at least 50% for all complexes (percent 
reduction at 22 or 24 h PI: 64Cu-CB-TR2A, 89.2%; 64Cu-NOTA, 80.1%; 64Cu-C3B-
DO2A, 50.4%; 64Cu-CB-DO2A, 95.6%; 64Cu-CB-TE2A, 99.1%). This results in 
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excretion of the complexes in the urine (Table 10). Excluding 64Cu-C3B-DO2A, the 
highest levels of 64Cu remaining in the blood and tissues at 24 h is observed for 64Cu-
NOTA as well as the lowest percent reduction from 1 to 24 h. These data 
demonstrate that the 64Cu-labeled cross-bridged chelates are cleared more 
completely from the blood, liver, and kidneys than the non-cross-bridged analogues, 
with 64Cu-CB-TE2A having the lowest amount of 64Cu remaining in the blood and 
tissues after 24 h.62 
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Figure 5. Selected organ biodistribution for 64Cu-C3B-DO2A, 64Cu-CB-TR2A, and 
64Cu-NOTA. Plotted with previously published data for 64Cu-CB-DO2A62 and 64Cu-
CB-TE2A63 for comparison. Note differences in scale. 
 
Table 10. Excretion data for 64Cu-C3B-DO2A and 64Cu-NOTA, 0 - 24 h PI. 
 % ID 
Complex Urine Feces 
64Cu-C3B-DO2A 46.0 ± 5.2 5.4 ± 1.2 
64Cu-NOTA 74.9 ± 7.1 4.4 ± 4.9 
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Discussion 
 It was initially proposed that cross-bridged chelators would form more stable 
complexes with copper radionuclides thereby improving pharmacokinetics of 64Cu-
labeled cross-bridged ligand biomolecule conjugated for enhanced imaging. 
Research has confirmed this hypothesis, demonstrating superior kinetic and in vivo 
stability of these chelators as carriers for copper radionuclides compared to 
traditional macrocyclic ligands.22, 62, 63 Greater kinetic stability improved target uptake 
and pharmacokinetics of cross-bridged ligand-peptide conjugates for molecular 
imaging purposes.25 In this work we investigated a second generation of cross-
bridged macrocyclic chelators of copper-based radiopharmaceuticals for imaging of 
cancer and other diseases. Pendant-armed cross-bridged cyclen and homocyclen 
derivatives were designed taking into consideration the convenience of synthetic 
routes, radiometal binding ability, and rapid complexation kinetics to enable efficient 
radiolabeling of proteins under mild conditions. The kinetic and thermodynamic 
properties of the coordination complexes were studied and correlation between these 
properties and desired in vivo behavior was examined. 
 Comparison of the crystal structures of Cu(II)-C3B-DO2A and Cu(II)-CB-
TR2A reveals strong similarities in the coordination geometry of these complexes. 
Both have cis-coordinating O’s with Jahn-Teller distortion along the N-Cu-O bond. 
This is consistent with previously published structures of Cu(II)-CB-TE2A and Cu(II)-
CB-DO2A.23, 62 Both Cu(II)-C3B-DO2A and Cu(II)-CB-TR2A are slightly “exo,” 
meaning that the metal protrudes from the ligand cleft, revealing the poor fit of the 
metal in the complex. The Cu(II)-CB-DO2A structure also reveals a protrusion of the 
Cu(II) from the ligand cleft.62 Cu(II)-CB-TE2A, however, has been shown to have a 
less pronounced Jahn-Teller distortion, and the copper cation fits snuggly in the cleft 
of the cross-bridged chelator.77 Stable coordination conformation, including how well 
the metal fits in the chelator, contributes to good in vivo stability.  
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 In vitro inertness of copper chelators has been investigated as a convenient 
indicator of in vivo stability. Aqueous acid-assisted decomplexation of 
polyazamacrocyclic copper complexes is a known indicator of their kinetic 
inertness.77 Comparison of the decomplexation half-lives suggested that Cu-C3B-
DO2A should be more stable than Cu-CB-TR2A in vivo although the biodistribution 
study did not confirm this. The acid decomplexation mechanism has not yet been 
elucidated, so the data should be interpreted with caution. 
The coordination preferences for Cu(II) and Cu(I) are significantly different, 
thus in vivo reduction of stable Cu(II) complexes to form Cu(I) products can lead to 
demetallation and transchellation to a variety of copper-binding biomolecules. The 
quasi-reversibility of Cu(II)-CB-TR2A compared to Cu(II)-CB-DO2A’s irreversible 
reduction, likely contributes to its superior in vivo behavior, relatively speaking. A 
quasi-reversible reduction was also reported for Cu-CB-TE2A.77 The quasi-
reversibility demonstrated by Cu-CB-TR2A suggests that, like CB-TE2A, the ligand is 
capable of adapting to a geometry suitable for Cu(I) coordination.57 The quasi-
reversibility is thought to stem from the ability of the molecule to adjust somewhat to 
the tetrahedral geometry favored by Cu(I).80 This malleability on the part of the 
chelator enhances the stability of the chelator in vivo, providing resistance to metal 
loss from the chelator upon reduction. 
 The reaction conditions for preparing 64Cu-C3B-DO2A (microwaving at high 
temperature) and 64Cu-CB-TR2A (basic ethanol) are relatively harsh compared to 
those for the conventional complexes, such as DOTA. NOTA, however, is easily 
radiolabeled with 64Cu using conditions compatible with protein conjugation (aqueous 
media at temperatures below 43 °C). The need for ha rsh radiolabeling conditions to 
form the complex is not indicative of complex stability in vivo. However, a positive 
correlation between the harshness of the conditions required for complex formation 
and the acid-decomplexation half-life has been observed. 
43 
 
 Evaluation of the biodistributions of the ligands shows rapid clearance of 
64Cu-CB-TR2A and 64Cu-NOTA through the blood, liver, and kidneys, consistent with 
what has been previously reported for 64Cu-labeled azamacrocyclic complexes.22, 62 
The initial high uptake and slow clearance of 64Cu-C3B-DO2A suggests poor in vivo 
stability and transchelation of 64Cu to proteins, as has been observed in previous 
studies.61, 81 Biodistribution of 64Cu-NOTA showed similar trends to 64Cu-CB-TR2A 
and CB-TE2A, but demonstrated a lower rate of clearance from liver and blood within 
24 h compared to the 64Cu-labeled cross-bridged complexes.  
Many parameters control the behavior of radiopharmaceuticals in biological 
media, and some of them cannot be easily predicted requiring in vivo studies. CB-
TE2A remains the best cross-bridged chelator for 64Cu and other copper 
radionuclides. Beyond the favorable in vitro characterization77, in vivo clearance and 
metabolism studies indicate the enhanced stability of 64Cu-CB-TE2A.62 The in vivo 
stability of Cu(II)-C3B-DO2A and Cu(II)-CB-TR2A complexes could be further 
evaluated by examination of the radiometabolites and determination of the extent of 
transchelation to proteins. 
 Previous work correlated acid stability and resistance to electrochemical 
reduction in aqueous conditions to biodistribution in normal rats, showing that 
biological stability might be predicted by thresholds of acid stability and reduction 
potentials.59, 77 While this does not hold for all of the compounds presented here, the 
in vitro characterization of BFCs remains a valuable tool for understanding the 
multifaceted in vivo biodistribution, stability, and metabolism of radiopharmaceuticals. 
A macrocyclic chelator with rapid complexation kinetics which also demonstrates 
kinetic inertness comparable to the previously studied 64Cu-CB-TE2A under 
physiological conditions has not yet been identified. Further research in developing 
Cu(II) chelators with even greater stability is clearly warranted. 
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CHAPTER 3 
 
In Vitro and In Vivo Investigation of Structurally Diverse 
64Cu-Labeled RGD Peptides for PET Imaging of αvβ3 Expression 
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Abstract 
 Integrin αvβ3 is upregulated in tumor vasculature, osteoclasts and areas of 
collateral circulation following ischemic injury. Here, we investigate structurally 
diverse bifunctional RGD (Arginine-Glycine-Aspartic acid) peptides for αvβ3 integrin 
affinity in vitro and in vivo. A series of peptides containing the RGD sequence were 
synthesized. Affinity to αvβ3 and specificity against αvβ5 and αIIbβ3 were determined in 
an isolated, competitive binding assay for the peptide alone and several peptide 
conjugates. A lactam-cyclized peptide (c(RGDyK)) demonstrated higher affinity for 
αvβ3 than disulfide-cyclized (KCRGDC) or linear peptide (GRGDS). Disulfide-cyclized 
peptides exhibited the best selectivity of the ligands investigated. A control, lactam-
cyclized peptide (c(RADyK)) has low affinity for all three integrins. Conjugation of 
Cu(II)-containing chelators did not affect the binding affinity or selectivity of the 
peptides. Cellular uptake studies in an αvβ3-positive cell line (U87MG human 
glioblastoma cells) were performed using four different 64Cu-DOTA-labeled peptides. 
In cell studies the disulfide-cyclized peptide showed the greatest amount of 
internalization. Uptake of RGD peptides could be blocked by high doses of unlabeled 
peptide. Internalization of the control peptide was minimal although receptor-
mediated surface binding was observed. Disulfide-linked KCRGDC exhibited the 
best in vitro behavior. Biodistribution studies in U87MG tumor-bearing nu/nu mice 
showed rapid uptake and retention of the 64Cu-labeled peptides in tumor with good 
tumor:blood and tumor:muscle ratios. At 4 h post-injection tumor:muscle ratios for all 
three compounds were similar, but 64Cu-DOTA-c(RGDyK) has a significantly higher 
tumor:blood ratio (p< 0.001). Uptake of 64Cu-DOTA-c(RGDyK) can be blocked by co-
administration of high doses of unlabeled peptide. Blocking of 64Cu-DOTA-KCRGDC 
and 64Cu-DOTA-GGRGDS uptake at 1 h was not attained with either co-injection or 
pre-injection (15 min or 1 h) of cold peptide. Small-animal PET/CT imaging of 64Cu-
DOTA-KCRGDC and 64Cu-DOTA-GGRGDS afforded visualization of the tumor, 
consistent with the biodistribution profiles. There was no observed difference 
46 
 
between block and non-block uptake (SUV at 4 h PI: 64Cu-DOTA-KCRGDC, 
0.79±0.17; 64Cu-DOTA-KCRGDC + block, 0.98±0.36; 64Cu-DOTA-GGRGDS, 
1.45±0.23; 64Cu-DOTA-GGRGDS + block, 1.58±0.075). Further in vivo investigation 
is warranted to demonstrate targeting specificity of the peptides along with 
investigation of a different peptide as a control. Higher binding affinity is being 
investigated through multimeric peptides and conjugation of several peptides onto 
the surface of nanoparticles. 
 
Introduction 
 Cell-cell and cell-matrix interactions play an important role in tumor 
metastasis and are essential during three specific processes: 1) dissociation of 
individual cells from the primary tumor and invasion of the adjacent tissue; 2) 
adherence in the capillary bed of the target organ; and 3) extravasation and arrest in 
the foreign tissue (Figure 1).82, 83 Integrins comprise one class of cell surface 
receptors participating in these cell adhesion processes. They are heterodimeric, 
transmembrane receptors composed of an α- and a β-subunit.28 There are 24 known 
mammalian heterodimer pairs arising from combinations of the 18 known α-subunits 
and 8 β-subunits. Among the most interesting members of the integrin family are 
αIIbβ3, also known as glycoprotein IIb/IIIa, which is involved in platelet aggregation,84 
and αvβ3, the vitronectin receptor. 
 Integrin αvβ3 is expressed in a variety of cell types including endothelial 
cells85, platelets86, osteoclasts38, 87, melanoma, and smooth muscle cells.30 This 
receptor is known to be over-expressed on many tumor cells, such as 
osteosarcomas, neuroblastomas, glioblastomas, breast, prostate, and invasive 
melanomas.31, 88, 89 Additionally, αvβ3 has been shown to be important during 
angiogenesis, tumor-induced and otherwise (Figure 1).90 Consequently, many 
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researchers are searching for high affinity, selective αvβ3 antagonists for diagnostic 
and therapeutic applications.91 
 
 
Figure 1. Targets for tumor imaging based on αvβ3-tageting tracers, such as labeled 
RGD peptides. Integrin αvβ3 is highly expressed on metastatic tumors and on 
endothelial cells undergoing angiogenesis. (Reprinted with permission from R. 
Haubner.83) 
 
 The amino acid sequence arginine-glycine-aspartic acid (RGD) is common to 
various extracellular matrix (ECM) proteins involved in cell-matrix adhesion, e.g. 
vitronectin, fibronectin, fibrinogen, thrombospondin, and von Willebrand factor.92 
Molecular interaction between these ECM proteins and integrins are known to 
mediate many biological processes.93 The RGD-binding site is involved in cell 
morphology, differentiation, proliferation, and gene expression.94 Many linear and 
cyclic peptides incorporating the RGD sequence have been developed to take 
advantage of these properties.95 
 The most prominent lead compound for development of radiotracers for non-
invasive determination of αvβ3 expression is the lactam-cyclized pentapeptide, 
cyclo(Arg-Gly-Asp-D-Phe-Val), which demonstrates high affinity for αvβ3.96 The first 
evaluation of this approach involved radioiodination of a series of RGD peptides.97-99 
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In vitro assays showed comparable affinity for αvβ3 and selectivity against αIIbβ3 as 
the lead structure. Receptor-specific tumor uptake was observed in vivo in nude mice 
bearing tumor xenografts of human melanoma (M21) and mammary carcinoma 
(MaCaF). Predominantly hepatobiliary clearance resulted in high activity 
concentration in liver and intestine. Strategies to improve pharmacokinetics of 
radiohalogenated peptides have been undertaken.  
 Glycosylation improved pharmacokinetics and increased activity uptake and 
retention in the tumor compared to the first-generation peptides.100 Conjugation of 
hydrophilic D-amino acids shifted elimination to the renal pathway.101, 102 However, 
tumor uptake was lower than observed with the glycosylated peptides. PEGylation is 
known to improve plasma stability, immunogenicity, and pharmacokinetics of 
peptides and proteins.74 Chen, et al. systematically studied the effects of various 
PEG moieties on radioiodinated103, F-18104, and Cu-64-labeled105 derivatives. The 
studies showed different effects of PEGylation on the pharmacokinetics, while tumor 
uptake and retention of RGD-peptides was dependent on the nature of the lead 
compound and minimally on the size of the PEG moiety. 
 Besides radiohalogenation, a variety of radiometal-based RGD tracers have 
been developed. Typically the ε-amino function of the lysine in the lead structure 
cyclo(Arg-Gly-Asp-D-Xaa-Val), where Xaa is Phe or Tyr, is conjugated with a 
chelating moiety. Van Hagen et al. coupled c(RGDyK) with DTPA for 111In labeling 
and demonstrated αvβ3 specific binding in newly formed vessels by autoradiography 
using human tumor tissue sections.96 Conjugation of the cystein-containing 
tetrapeptide sequence H-Asp-Lys-Cys-Lys-OH or macrocyclic chelator DOTA to 
cyclo(Arg-Gly-Asp-D-Phe-Lys) allowed for the preparation of 99mTc-, 188Re- and 90Y-
labeled analogues.106 All of these compounds exhibit high receptor affinity and 
selectivity as well as specific tumor accumulation. However, the pharmacokinetics of 
most of them need improvement. 
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 Phage display has generated additional RGD derivatives. RGD-4C ((Cys2-
Cys10, Cys4-Cys8)H-Ala-Cys-Asp-Cys-Arg-Gly-Asp-Cys-Phe-Cys-Gly-OH) contains 
two disulfide bridges and binds with moderate affinity to both αvβ3 and αvβ5.107 A 
shortened derivative of RGD-4C coupled with HYNIC and labeled with 99mTc was 
found to have only marginal tumor uptake which can be explained by the modest 
αvβ3 binding affinity.108, 109 Conjugation with HYNIC, deletion of the terminal amino 
acids, or labeling with 99mTc impairs the affinity to integrin αvβ3 resulting in a peptide 
not suitable for in vivo imaging. 
 Apart from the cyclic structures, a few linear peptides have been investigated. 
Using a new labeling strategy allowing for 18F-labeling of peptides on a solid support, 
4-[18F]fluorobenzyl-Lys-Pro-Gln-Val-Thr-Arg-Gly-Asp-Val-Phe-Phe-Glu-Gly-NH2 was 
synthesized.110 Despite exhibiting high αvβ3 binding affinity, biodistribution studies 
and PET images showed low activity accumulation in the tumor. Analysis of blood 
and urine samples revealed no intact peptide present as soon as 5 min post-
injection, indicating that the linear peptide is metabolically unstable. A linear 
decapeptide (Arg-Gly-Asp-Ser-Cys-Arg-Gly-Asp-Ser-Tyr) containing two RGD sites 
and labeled with 99mTc via the Cys5 within the peptide was studied in 14 patients with 
melanoma.111 Despite a fast renal clearance rate, the peptide localized to most 
metastatic melanoma lesions with specific tumor accumulation. Tumor-to-
background ratios were generally low due to high lung and abdomen background 
activity levels. Some small linear peptides, e.g. GRGDSPK, are reported to have low 
selectivity for distinct integrin subtypes, but the affinity and selectivity of such tracers 
has not been described thus far.112, 113  
 Multimeric compounds presenting more than one RGD site have been 
introduced. Janseen et al. synthesized a dimeric peptide by coupling two cyclo(Arg-
Gly-Asp-D-Phe-Lys) units via a glutamic acid linker with DOTA or HYNIC conjugated 
to the free amino function of the linker moiety for radiolabeling.114, 115 Technetium-
99m-HYNIC-E-[c(RGDfK)]2 exhibited a 10-fold higher affinity for αvβ3 than the 
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monomeric 99mTc-HYNIC-c(RGDfK). The groups of Kessler and Wester carried out a 
systematic study on the influence of multimerization on receptor affinity and tumor 
uptake.116, 117 A PEG linker and lysine moieties connected different numbers of 
c(RGDfE) peptides. An in vitro binding affinity assay and PET images show 
increasing affinity in the series monomer, dimer, tetramer, and octamer. Many other 
groups have had varying degrees of success with multimerization.118-121 Overall, 
multimerization leads to increased binding affinity and tumor uptake as well as 
retention. Through the use of appropriate linker moieties, the pharmacokinetics of the 
peptide-based tracer can be improved. 
 A wide variety of non-peptide low molecular weight compounds 
(petidomimetics) have been developed based on structure-activity investigations in 
the past decade. These will not be reported upon here, but they have been 
extensively reviewed elsewhere.122-127 
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Figure 2. The standard RGD sequence in comparison with high affinity ligands for 
integrin αvβ3. (A) A schematic representation of the RGD binding motif. Specificity 
and affinity for αvβ3 has been introduced in peptide ligands by ring closure and 
flanking amino acids, which force the arginine and aspartic acid side-chains into the 
proper conformation. In RGD-mimetics, the two domains that interact with the 
integrin (Arg and Asp) have been replaced by a guanidine binding site and 
carboxylate group. (B) Structures of c(RGDf(N-Me)V), RGD4C, and the quinolone 
vitronectin receptor antagonist SH066 described by Harris et al.128 All are high affinity 
ligands for αvβ3. (Figure adapted from Temming et al.129) 
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 As mentioned above, most of the integrin super-family members recognize 
the RGD tripeptide sequence, an epitope shared by a variety of extracellular ligands. 
Structural similarities within the integrin family and between their respective ligands 
make selectivity a major concern in the design of potential diagnostic imaging and 
therapeutic agents.130 The affinity of RGD peptides for their ligands may be affected 
by steric conformation of the peptide.131-133 The RGD sequence assumes very 
different conformations in different proteins, which have similar affinities to cell 
attachment134, 135 and disintegrins.136-138 The RGD sequences of these proteins are 
almost always located in flexible loop regions. Amino acids flanking RGD have also 
been suggested to affect the selectivity and affinity of peptides toward integrins.139, 140 
In addition to direct interactions between these residues and the integrin, flanking 
groups influence the folding of the peptide and the conformational features of the 
RGD-motif. Cyclization is commonly employed to improve the binding properties of 
RGD peptides. By conferring rigidity to structure, it improves the selectivity of the 
“promiscuous” RGD-sequence for a specific integrin sub-type.129 Systematic 
substitution studies have shown that the positive and negative charges of the 
argenine (R) and aspartic acid (D) side chain functionalities and the unmodified 
glycine (G) spacer residue are critical.141, 142 Most RGD peptidomimetics studied as 
αvβ3 antagonists share a common pattern, consisting of a rigid, preferably achiral 
core unit, which links a guanidine type functionality and a carboxylic moiety.122 
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Figure 3. Structurally diverse RGD peptides characterized in this study, including 
lactam-cyclized, disulfide-cyclized, and linear RGD derivatives and a lactam-cyclized 
control peptide. 
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 Here, we investigate structurally diverse bifunctional RGD peptides for αvβ3 
integrin affinity in vitro and in vivo. Lactam-cyclized, disulfide-cyclized, and linear 
RGD derivatives and a lactam-cyclized control peptide were synthesized or 
purchased with and without the macrocyclic chelator DOTA for radiolabeling with 
64Cu (Figure 3). The in vitro binding affinity of the four RGD peptides towards integrin 
αvβ3 was studied in a plate-based competitive binding assay as well as specificity 
against αvβ5 and αIIbβ3 using the same assay. Cellular uptake studies in an αvβ3-
positive cell line (U87MG human glioblastoma cells) were performed using the four 
different 64Cu-DOTA-labeled peptides. In vivo properties were studied via 
biodistribution studies and small-animal PET imaging in U87MG tumor-bearing nu/nu 
mice. 
 
Experimental Procedures 
 General materials and instrumentation. All solvents and chemicals were 
reagent grade and used without further purification unless otherwise noted. N-
hydroxybenzotriazole (HOBt) and the Fmoc-protected amino acids were purchased 
from AnaSpec (San Jose, CA). Trifluoroacetic acid (TFA) and N,N-
diisopropylethylamine (DIEA) were purchased from Advanced ChemTech (Louisville, 
KY). Dichloromethane (DCM), N, N-dimethyformamide (DMF), methanol, and 
acetonitrile were from purchased from Fisher Scientific (Pittsburgh, PA). 1,4,7,10-
Tetraazacyclododecane-1,4,7-tris(t-butyl acetate)-10-aceitc acid  (DOTA-(3OBut)-
COOH) was purchased from Macrocyclics (Dallas, TX). Diisopropylcarbodiimide 
(DIC) and other commercial chemicals were purchased from Sigma-Aldrich (St. 
Louis, MO). The peptides and derivatives were obtained from a variety of sources: 
KCRGDC and GRGDS were custom synthesized by Tianma Pharma Co. (Suzhou, 
China); DOTA-GGRGDS was custom synthesized by C.S Bio Company, Inc. (Menlo 
Park, CA); and c(RGDyK) was purchased from Peptides International, Inc. 
(Louisville, KY). Yunpeng Ye synthesized DOTA-c(RGDyK) and DOTA-KCRGDC. 
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Vitronectin, fibronectin, αvβ3 and αvβ5 were purchased from Chemicon (a division of 
Millipore; Bellerica, MA). Integrin αIIbβ3 was purchased from EMD Chemicals, Inc. 
(Gibbstown, NJ). All solutions were prepared using water which had been distilled 
and then deionized (18 MΩ/cm2) by passing through a Milli-Q water filtration system 
(Millipore Corp.; Bedford, MA). Trace metals were removed from all buffers used for 
radiolabeling by Chelex 100 resin (BioRad Laboratories; Hercules, CA). Whatman 
C18 silica gel TLC plates (KC18F, 60 Å, 200 µm) were purchased from Fisher 
Scientific (Pittsburgh, PA). Copper-64 was prepared on a biomedical cyclotron at 
Washington University Medical School by the 64Ni(p,n)64Cu nuclear reaction at high 
specific activity as previously described.103 Female nu/nu mice were purchased from 
Charles River Laboratories (Boston, MA). ES-MS was accomplished using a Waters 
Micromass ZQ (Millford, MA). Radio-TLC was accomplished using a Bioscan 200 
imaging scanner (Bioscan, Inc., Washington, DC). Analytical reversed-phase HPLC 
was performed on a Waters 600E (Milford, MA) chromatography system with a 
Waters 991 photodiode array detector and an Ortec Model 661 radioactivity detector 
(EG&G Instruments, Oak Ridge, TN). Radioactive samples were counted with a 
Beckman 8000 automated well-type gamma counter (Beckman Instruments, Inc.; 
Fullerton, CA) or a Wallac Wizard 1480 automatic gamma counter (Perkin Elmer; 
Gaithersburg, MD). 
 HPLC purification and analysis for peptide synthesis. HPLC analysis was 
performed with a Vydac C-18 column (250×4.6 mm) at a flow rate of 1.0 mL/min. 
Semi-preparative HPLC was performed with a Vydac C-18 column (25×2.2 cm) at 
9.5 mL/min. HPLC eluents consist of  water containing 0.05% TFA (solvent A) and 
acetonitrile containing 0.05% TFA (solvent B). The elution profile was monitored by 
UV absorbance at 254 nm and 214 nm.  
 Solid phase peptide synthesis of H-DTyr(But)-Lys(Dde)-Arg(Pbf)-Ala-
Asp(OBut)-OH. The protected peptide sequence was assembled manually from H-
Asp(But) 2-chlorotrityl resin (0.81 g, 0.64 mmol/g) using the conventional Fmoc 
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chemistry in a glass reaction vessel fitted with a sintered glass frit. The coupling 
reactions were carried out by adding a pre-activated solution of N-α-Fmoc-protected 
amino acid (1.2 mmol), HOBT (1.2 mmol), HBTU (1.2 mmol), and DIEA (2.4 mmol) in 
anhydrous DMF (3 mL/g resin) into the resin and swirling for 2 h. The progress of the 
coupling was monitored by Kaiser test. The Fmoc protecting groups were removed 
with a solution of 20% piperidine in DMF (10 min, 2x). The resin was washed with 
methanol (1 min, 2x), followed by DMF (1 min, 6x). The penta-peptide, H-DTyr(But)-
Lys(Dde)-Arg(Pbf)-Ala-Asp(OBut)-OH, was cleaved by swirling the resin in 
trifluoroacetic acid/dichloromethane (1:99 v:v) for 5 min. The filtrate was added to a 
solution of pyridine/methanol (5 mL/10 mL). The resin was washed with methanol 
(2x) and dichloromethane (2x). The cleavage procedure described above was 
repeated five more times and the combined filtrate was concentrated, washed with 
water, and dried to give the title compound (480 mg, 94% yield).  
 Cyclo[DTyr(But)-Lys-Arg(Pbf)-Ala-Asp(OBut)]. The peptide obtained above 
was added dropwise into a solution of PyBOP (520 mg, 1 mmol), HOBT(135 mg, 1 
mmol), and DIEA (260 mg, 2 mmol) in DMF/DCM (1000 mL, 10:90 v:v). The mixture 
was stirred overnight, concentrated, and washed with water, 5% aqueous potassium, 
and water. The solid was dissolved in methanol (100 mL) containing hydrazine (1.0 
mL). The mixture was stirred for 15 min, concentrated, and washed with aqueous 
NaHCO3 solution (5%) and water. The title compound was further purified by flash 
column chromatography on silica gel using a mixture of methanol, DCM, and DIEA 
as eluent (155 mg, 35% yield).  
 Cyclo[DTyr-Lys(DOTA)-Arg-Ala-Asp]. A mixture of the peptide obtained 
above (80.0 mg, 0.08 mmol), DOTA(3OBut) (82.0 mg, 0.24 mmol), HOBT (32.4 mg, 
0.24 mmol), and DIC (100.8 mg, 0.80 mmol) in DMF (1.2 mL) was stirred for 72 h. 
The mixture was filtered, concentrated, and stirred in aqueous TFA (95:5 v:v, 3 mL) 
for 2 h. The resulting mixture was added to a solution of cold MBTE (10 mL). The 
precipitate was collected by centrifugation and purified by HPLC (gradient from 3% to 
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50% over a period of 20 min and then isocratic at 50% for 10 min). The desired 
fractions were characterized by both ES-MS and HPLC, combined, and lyophilized to 
afford the title compound  (19 mg, ~15% yield), observed m/z for [MH]+ and [MH2]2+ 
in ES-MS: 1019.5 and 510.25.  
 Integrin binding assay. An isolated, competitive binding assay described 
previously is utilized here. Briefly, vitronectin (Vn) and fibronectin (Fn) were 
biotinylated with N-hydroxysuccinimide biotin (2 h at room temperature) before 
dialysis into PBS, pH 7.4. The wells of a 96-well plate (Nunc Immuno Plate with 
MaxiSorp) were coated with 100 µg integrin αvβ3, αvβ5, or αIIbβ3 in coating buffer (20 
mM Tris, pH 7.4, 150 mM NaCl, 2 mM CaCl2, 1 mM MgCl2, 10 µM MnCl2). The plates 
were then blocked (1 h at 4 °C) with bovine serum alb umin (BSA) (3% in coating 
buffer). After washing three times with binding buffer (0.1% BSA in coating buffer), 
biotinylated Vn for integrins αvβ3 and αvβ5, or biotinylated Fn for integrin αIIbβ3, (final 
concentration 14 nM) with and without serially diluted ligands was allowed to bind to 
the integrins (3 h at 37 °C). After washing (200 µL binding buffer, 3x), bound 
biotinylated ligand was detected by binding ExtrAvidin alkaline phosphatase 
(1/35,000 dilution, 1 h at room temperature) and using the p-nitrophenyl phosphate 
substrate solution as the chromogen. Each concentration data point was done in 
triplicate, and each binding experiment was performed at least twice. Nonlinear 
regression was used to fit binding curves and calculate inhibitory concentrations of 
50% (IC50 value). A control assay was performed concurrently with all experiments to 
ensure the accuracy of the procedure and reagents. 
 Radiolabeling with 64Cu. Each of the DOTA-RGD-peptide constructs was 
radiolabeled with 64Cu in aqueous solution following the general procedures for 
radiolabeling non-cross-bridged ligands that have been previously described.79 In 
brief, no-carrier-added 64CuCl2 was added to a 5 mM solution of DOTA-peptide 
conjugate in 0.1 M NH4OAc, pH 8 and heated at 37 °C for 45 – 90 min. Specif ic 
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activities ranging from 1 - 2.8 mCi/µg were obtained. Radiochemical purity of ≥ 95 % 
was verified by radio-TLC and radio-HPLC. 
 Cellular internalization assay. The U87MG human gliobastoma cell line 
(integrin αvβ3-positive) was obtained from American Tissue Culture Collection 
(Manassas, VA) and maintained at 37 °C in a humidified  environment containing 5 % 
CO2 in Eagle’s Minimum Essential medium (with Earle’s BSS and 2mM L-glutamine) 
(MEM) supplemented with 10% fetal bovine serum (Invitrogen Corp., Carlsbad, CA). 
For cell assays, cells were grown until 65–75 % confluent before being harvested by 
incubation at 37 °C for two min in trypsin/EDTA soluti on. The cell samples were 
centrifuged at 110 g for 5 min. The cell pellets were rinsed with growth medium (2 x 1 
mL) and resuspended in the binding medium (MEM, 1 % glutamine, 1 % BSA, 0.1 
mM Mg2+, 0.1 mM Mn2+) (1×106 cells/(0.5) mL) in microfuge tubes. The 64Cu-DOTA-
peptide solution (1 nM, ~5 µCi in 20-30 µL) was added to the cell suspension, and 
the samples were incubated (37 °C, 5 % CO 2) with rotation for 15, 30, 60, 90 min. 
For block experiments the samples were administered 1 µM non-radioactive peptide 
solution (50 µL) 15 min prior to addition of the 64Cu-DOTA-peptide solution. At 
appropriate time points, the samples were centrifuged for 1 min at 110 g and the 
radioactive medium was aspirated. Cell pellets were rinsed with ice cold binding 
buffer (0.5 mL) and centrifuged for 1 min at 110 g (2x). Suspension of the cells in 
acidic wash buffer (HBSS containing 20 mM NaOAc (pH 4.0)) (0.5 mL, 2x) and 
incubation at 37 °C for 10 min was used to isolate the surface bound fraction. The 
cells were separated from the surface bound fraction by centrifugation and collection 
of the supernatant; the resulting two acid wash fractions were combined. The cell-
internalized fraction was obtained by lysing the cell pellets in lysis buffer (1 mL 0.5 % 
SDS in PBS). The radioactivity in each fraction was measured in a well-type gamma 
counter. Total protein concentration was determined using the bicinchoninic acid 
protein assay (Pierce Biotechnology, Rockford, IL). Uptake was normalized by 
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expression as % activity administered per milligram of protein. Each peptide and time 
point was done in triplicate. 
 Biodistribution studies. Animal experiments were carried out under humane 
conditions and in compliance with the Guidelines for the Care and Use of Research 
Animals established by Washington University’s Animal Studies Committee. Female 
athymic nude mice (nu/nu) (6 wk old) were given subcutaneous injections at the 
nape of the neck with 5 x 106 U87MG glioblastoma cells suspended in a minimal 
volume of PBS. After 3.5 weeks the tumor-bearing mice were subject to 
biodistribution and small-animal PET imaging studies.  
 Tissue distribution studies were performed after intravenous injection of the 
radiolabeled compound via the tail vein (20-30 mCi in 100-150 µL). A blocking 
experiment was also performed by coinjecting radiotracer with a saturating dose of 
cold peptide (18 mg/kg mouse body weight). Tissue biodistribution data were 
obtained at 1, 4, and 24 h post injection (PI) and 1 h block (n = 5 per time point). 
Animals were sacrificed at the appropriate time points, organs of interest, including 
tumor, were removed and weighed, and the radioactivity was measured in a gamma 
counter along with dose standards. The raw counts were decay corrected to a 
standard time, and the counts were normalized as the percent total inject dose per 
gram of tissue (%ID/g) and percent injected dose per organ (%ID/organ). Mice were 
allowed food and water ad libitum. 
 microPET imaging. Whole-body small animal PET imaging was performed 
on a microPET Focus 120 or 220 small-animal PET scanner (CTI-Concord 
Microsystems LLC, Knoxville, TN). Mice anesthetized with 1-2 % isoflurane were 
imaged for 10 min at 1, 4 and 24 h after tail vein injection of the 64Cu-DOTA-peptide. 
Co-registration of the small-animal PET images was achieved in combination with a 
microCAT-II small-animal CT camera (CTI-Imtek Inc., Knoxville, TN) which provides 
high-resolution CT anatomic images. Co-registration of microPET and microCAT 
images was accomplished through a landmark registration technique with image 
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display software (Amira, TGS Inc.) using fiducial markers directly attached to the 
animal bed. Maximum a posteriori (MAP) reconstruction was used for the PET 
component of the co-registered images. Regions of interest (ROI) were drawn 
manually based on co-registered small-animal CT images, and ROI activity on the 
corresponding small-animal PET images was measured using Amira 4.0 software 
(Visage Imaging Inc., San Diego, CA). These values were converted to standard 
uptake values (SUVs) using equation 1. 
tissue concentration (µCi/g)
injected dose (µCi) / body weight (g)
SUV = 
  (Eq. 1) 
After imaging, the mice were sacrificed for post-PET biodistribution, as described 
above. 
 Statistical methods. All data are presented as the mean ± standard 
deviation. Group comparisons were made using standard ANOVA methods. Post-hoc 
testing of individual group differences was accomplished with the Bonferroni test. 
Groups with p < 0.05 were considered significantly different. GraphPad Prism 
software (version 5.02; San Diego, CA) was used for all statistical analyses. 
 Collaborators. Synthesis of the peptides described in the experimental 
section was carried out in the laboratory of Dr. Sam Achilefu by ALF. Details for the 
synthesis of DOTA-c(RGDyK) and DOTA-KCRGDC by Yunpeng Ye can be found in 
Appendix II. 
 
Results 
 Solid phase peptide synthesis. As shown in Scheme 1, the cyclic protected 
RGD peptide i.e. cyclo[R(Pbf)GD(OBut)y(But)K] was similarly prepared as reported 
previously. The linear protecting peptide H-D(OBut)y(But)K(Dde)R(Pbf)G-OH was 
assembled from H-Gly-2-chlorotrityl resin using conventional Fmoc chemistry and 
then cleaved with 1% TFA in DCM. The crude product was cyclized in the presence 
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of PyBOP/HOBT/DIEA in a diluted solution in DCM/DMF (90:10). The resulting cyclic 
protected peptide i.e. cyclo[R(Pbf)GD(OBut)y(But)K(Dde)] was further de-protected 
with 2% hydrazine in methanol to afford the desired amino-containing analog i.e. 
cyclo[R(Pbf)GD(OBut)y(But)K], which was confirmed by ES-MS. This peptide was 
conjugated with DOTA(3OBut)-COOH in the presence of HOBT and DIC to give  
cyclo[R(Pbf)GD(OBut)y(But)K(DOTA(3OBut)] which was de-protected with TFA. The 
crude product was purified by semi-preparative HPLC to get the desired product, i.e. 
cyclo[RGDyK(DOTA)].  
 
H-Asp(OBut)-DTyr(But)-Lys(Dde)-Arg(Pbf)-Gly-OH-Gly-O
Reagents and conditions: 
1. Fmoc chemistry; 2. a) TFA/DCM(1:99); b) Pyridine/DCM/Methanol; 
3. PyBOP/HOBT/DIEA/DMF/DCM; 4. Hydrazine/methanol(1:100); 
5.DOTA(3OBut)-COOH/HOBT/DIC/DMF; 6. TFA/water(95:5).
1
2
3
4
Cyclo{DTyr(But)-Lys[DOTA(3OBut)]-Arg(Pbf)-Gly-Asp(OBut)}
5
6
H-Asp(OBut)-DTyr(But)-Lys(Dde)-Arg(Pbf)-Gly-OH
Cyclo[DTyr(But)-Lys(Dde)-Arg(Pbf)-Gly-Asp(OBut)]
Cyclo[DTyr(But)-Lys-Arg(Pbf)-Gly-Asp(OBut)]
Cyclo[DTyr-Lys(DOTA)-Arg-Gly-Asp]
 
Scheme 1. Synthesis of cyclo[RGDyK(DOTA)] 
 
 As summarized in Scheme 2, the resin-bound linear protected peptide i.e. 
Fmoc-Lys(Boc)-Cys(Acm)-Arg(Pbf)-Gly-Asp(OBut)-Cys(Acm)-Rink amide resin was 
assembled from Fmoc-Rink amide resin using Fmoc chemistry. The disulfide bond 
was formed with thallium trifluoroacetate in DMF on solid support.  After the Fmoc at 
the N-terminus was deblocked with 20% piperidine in DMF, the DOTA(3OBut)-COOH 
was attached in the presence of HOBT and DIC. Finally, the desired product, i.e. 
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DOTA-K-cyclo(CRGDC)-NH2, was obtained by cleavage with TFA/water (95:5) was 
purified by HPLC. The two desired products were identified by both ES-MS and 
analytical HPLC.  
 
Reagents and condition: 1. Peptide assembly using Fmoc chemistry; 2. Tl(CF3COO)3/DMF; 
3. (a) piperidine/DMF(20%); (b) DOTA(3OBut)/HOBT/DIC/DMF; 4. TFA/water(95:5).
Fmoc-NH Fmoc-Lys(Boc)-Cys(Acm)-Arg(Pbf)-Gly-Asp(OBut)-Cys(Acm)1
Fmoc-Lys(Boc)-Cys-Arg(Pbf)-Gly-Asp(OBut)-Cys-NH2
S S
DOTA(3OBut)-Lys(Boc)-Cys-Arg(Pbf)-Gly-Asp(OBut)-Cys-NH3
S S
4
S S
DOTA-Lys-Cys-Arg-Gly-Asp-Cys-NH2
 
Scheme 2. Synthesis of DOTA-K-cyclo(CRGDC)-NH2. 
 
 The cyclic control peptide was prepared in three steps consisting of solid 
phase peptide synthesis, intramolecular cyclization in solution, and conjugation of 
peptide with DOTA, as shown in Scheme 3. Briefly, the orthogonally protected linear 
peptide [DTyr(But)-Lys(Dde)-Arg(Pbf)-Ala-Asp(OBut)-O-Resin] was prepared on a 2-
chlorotrityl resin and cleaved with 1% TFA in dichloromethane (DCM). After cyclizing 
the protected peptide in a solution of PyBOP (2.5 equiv), HOBT (2.5 equiv), and 
DIEA (5 equiv) in DMF/DCM (1:10 v:v), the Dde group was selectively removed with 
1% hydrazine in methanol. DOTA(3OBut) (3 equiv) was conjugated to the free ε-
amino lysine group of the peptide (1 equiv) in the presence of DIC (10 equiv), and 
HOBT (3 equiv) in anhydrous DMF. All side-chain protecting groups were removed 
with 95% aqueous TFA solution and the crude product was purified by HPLC and 
identified by ES-MS.  
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H-DTyr(But)-Lys(Dde)-Arg(Pbf)-Ala-Asp(OBut)-OH-Asp(OBut)-O
Cyclo[DTyr(But)-Lys(Dde)-Arg(Pbf)-Ala-Asp(OBut)]
Cyclo[DTyr(But)-Lys-Arg(Pbf)-Ala-Asp(OBut)]
Reagents and conditions: 1. Fmoc chemistry; 2. a) TFA/DCM(1:99); b) Pyridine/DCM/Methanol; 
3. PyBOP/HOBT/DIEA/DMF/DCM; 4. Hydrazine/methanol(1:100); 
5. DOTA(3OBut)/HOBT/DIC/DMF; 6. TFA/water(95:5).
1
2
3
4
Cyclo[DTyr(But)-Lys(DOTA(3OBut))-Arg(Pbf)-Ala-Asp(OBut)]
5
Cyclo[DTyr-Lys(DOTA)-Arg-Ala-Asp]
6
H-DTyr(But)-Lys(Dde)-Arg(Pbf)-Ala-Asp(OBut)-OH
 
Scheme 3. Synthesis of cyclo[RADyK(DOTA)] 
 
 Integrin binding assay. Inhibitory effects of structurally diverse RGD 
peptides were quantified by measuring their effects on the interactions between 
immobilized integrin and biotinylated soluble Iigands (Table 1). Figure 4 shows 
representative IC50 binding curves of GRGDS towards integrins αvβ3, αvβ5, and αIIbβ3. 
The IC50 values obtained in replicate experiments were within the same confidence 
interval. The ability of the peptides to inhibit the binding of vitronectin to the isolated 
immobilized αvβ3 and αvβ5 receptor was compared with the previously published 
values for c(RGDyK). In some instances inhibitory peptides were able to suppress 
fully the binding of ligands to the isolated receptors. All the binding kinetics followed 
a classic sigmoid path and could be fit with a nonlinear regression curve. According 
to the IC50 values obtained, KCRGDC has the best selectivity for integrin αvβ3 and its 
binding specificity is comparable to c(RGDyK), which has the lowest IC50 value. 
Whereas Haubner et al. found selectivity of all peptides to be similar, with biological 
activities about 4000 times higher for the αvβ3 integrin over αIIbβ3, that trend was only 
observed here for the disulfide-cyclized KCRDGDC. The lactam-cyclized peptide, 
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c(RDGyK), was found to have a 30-fold better affinity for αIIbβ3 compared to αvβ3. 
This was surprising but has not been further investigated. A previous study by Pfaff 
et al., using a similar binding assay, reported a similar affinity of the linear peptide 
GRGDS towards αvβ3 and αIIbβ3 as was observed here (30-fold increase verse 55-
fold increase). 
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Figure 4. IC50 binding curves for GRGDS versus vitronectin for integrins  
αvβ3 and αvβ5 and versus fibronectin for αIIbβ3 (n=3). 
 
 
Table 1. Inhibition of Vitronectin Binding to Immobilized αvβ3 and αvβ5 and Fibrinogen 
Binding to Immobilized αIIbβ3 in a Competative Heterologous Binding Assay. 
 IC50 
 αvβ3 (nM) αvβ5 (nM) αIIbβ3 (nM) 
c(RGDyK) 3.7a 194a 0.11 
KCRGDC 10.4 921 > 5,000 
GRGDS 15.9 > 5,000 873 
c(RADyK) 1,400 > 5,000 > 5,000 
a: previously published values103 
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 Cellular internalization assay. Cell-based assays were performed with 
64Cu-DOTA-peptides to measure the internalization efficiency of the peptides in 
U87MG glioblastoma cells. Internalization of the radioactivity as well as total cell 
associated activity were measured at several time-points over 90 min and 
normalized to protein content (Figure 5). In order to better visualize the differences 
between the compounds, internalization and total cell associated activity of all four 
compounds after 60 min are presented on one graph (Figure 6). For the three 64Cu-
DOTA-RGD compounds, total cell associated activity continues to increase for the 
entire time although internalization does not. The disulfide-cyclized 64Cu-DOTA-
KCRGDC has statistically significant higher levels of non-blocked internalization (p < 
0.001) and total cell associated activity (p < 0.05) compared to the three other 
compounds. The binding and internalization trends of 64Cu-DOTA-GGRGDS and 
64Cu-DOTA-c(RGDyK) are the same with slightly less uptake observed for 64Cu-
DOTA-c(RGDyK), although not statistically significant. Binding and uptake of 64Cu-
DOTA-RGD peptides could be blocked by addition of excess cold peptide. 
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Figure 5. Comparison of cellular internalization and cell-associated activity in 
U87MG cells over time (n = 3). (A) 64Cu-DOTA-KCRGDC, block with KCRGDC; (B) 
64Cu-DOTA-GGRGDS, block with GRGDS; (C) 64Cu-DOTA-c(RGDyK), block with 
c(RGDyK); (D) 64Cu-DOTA-c(RADyK), block with c(RGDyK). Note the different y-axis 
scale used for (A) and (D). 
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 Specific, blockable cell surface binding is observed for 64Cu-DOTA-c(RADyK), 
although only minimal internalization is observed. Total cell associated (p < 0.001) 
and internalization (p < 0.05) without blocking are significantly lower for the control 
compared to the RGD peptides.  
 
 
 
Figure 6. Comparison of cellular internalization and cell-associated activity at 60 min 
in U87MG cells for four 64Cu-DOTA-peptides (n = 3). 
 
 In vivo characterization. Small-animal PET and CT co-registration was 
performed with two of the 64Cu-DOTA-peptide constructs, 64Cu-DOTA-KCRGDC and 
64Cu-DOTA-GGRGDS (n = 2 with and without block), simultaneously with 
biodistribution studies. Biodistribution was also performed with 64Cu-DOTA-
c(RGDyK). A comparison of biodistribution in selected organs is presented in Figure 
7, showing rapid uptake and retention of the 64Cu-labeled peptides in tumor. 
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Figure 7. Comparison of biodistribution of selected organs in U87MG tumor-bearing 
nu/nu mice (n = 5). (A) 64Cu-DOTA-KCRGDC, block with KCRGDC; (B) 64Cu-DOTA-
GGRGDS, block with GRGDS; (C) 64Cu-DOTA-c(RGDyK), block with c(RGDyK).  
(* p < 0.05 compared to non-blocked.) 
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 Significantly higher levels of uptake were observed for 64Cu-DOTA-KCRGDC 
across all organs. As observed in the cell studies, 64Cu-DOTA-GGRGDS and 64Cu-
DOTA-c(RGDyK) have similar profiles. The disulfide-cyclized peptide was the only 
compound observed to have increased tumor uptake from 4 to 24 h PI (64Cu-DOTA-
KCRGDC, 9.4% increase; 64Cu-DOTA-GGRGDS, 20.4% decrease; 64Cu-DOTA-
c(RGDyK), 22.5% decrease). This was also the only peptide to have continuous 
blood clearance over the 24 h period (from 1 to 24 h PI: 64Cu-DOTA-KCRGDC, 
28.4% decrease; 64Cu-DOTA-GGRGDS, 28.2% incease; 64Cu-DOTA-c(RGDyK), 
1.0% increase). The increased blood activity observed for 64Cu-DOTA-GGRGDS 
suggests that the compound is unstable in vivo which would contribute to its overall 
poor biodistribution. All three compounds have similar rates of clearance for liver and 
kidney (percent reduction in kidney from 1 to 24 h: 64Cu-DOTA-KCRGDC, 18.4%; 
64Cu-DOTA-GGRGDS, 30.8%; 64Cu-DOTA-c(RGDyK), 27.9%) (percent reduction in 
kidney from 1 to 24 h: 64Cu-DOTA-KCRGDC, 46.8%; 64Cu-DOTA-GGRGDS, 50.4%; 
64Cu-DOTA-c(RGDyK), 73.3%). Tumor uptake of 64Cu-DOTA-c(RGDyK) can be 
blocked by co-administration of high doses of unlabeled peptide (1 h PI: non-block, 
1.8875±0.2396; block, 0.7723±0.1458 (p < 0.05)). Blocking of 64Cu-DOTA-KCRGDC 
and 64Cu-DOTA-GGRGDS uptake at 1 h was not attained with either co-injection or 
pre-injection (15 min or 1 h) of cold peptide (pre-blocking data not shown). 
 Good tumor:blood and tumor:muscle ratios were observed for the three 
compounds tested. At 4 h post-injection tumor:muscle ratios for all three compounds 
were similar (Figure 8). The lactam-cyclized 64Cu-DOTA-c(RGDyK) has a 
significantly higher tumor:blood ratio (p< 0.001).  
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Figure 8. Comparison of tumor:background tissue ratios. (*p < 0.001 compared to 
64Cu-DOTA-c(RGDyK).) 
 
 The coregistered PET/CT images shown in Figures 9 and 10 are 
representative of all mice in each group (n = 2). In coronal and transaxial sections 
uptake in the tumor can be visualized. As observed in the biodistribution study at 1 h, 
there is no significant difference between those animals receiving a blocking dose of 
peptide or not at 1, 4, or 24 h PI (SUV at 4 h PI: 64Cu-DOTA-KCRGDC, 0.79±0.17; 
64Cu-DOTA-KCRGDC + block, 0.98±0.36; 64Cu-DOTA-GGRGDS, 1.45±0.23; 64Cu-
DOTA-GGRGDS + block, 1.58±0.075) (Figure 11). The best tumor visualization was 
obtained at 4 h PI and is supported by the highest SUV values of the three time 
points. Following the 24 h imaging timepoint, a post-PET biodistribution was 
performed (Figure 12). The activity distributions are comparable to those observed in 
the other biodistribution studies (Figure 7) and support the imaging observations. At 
24 h there is not statistically significant difference in tracer uptake and retention 
between animals receiving a dose of cold peptide block at time 0 and those which 
did not.  
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Figure 9. Small-animal PET/CT of 64Cu-DOTA-KCRGDC uptake in U87MG tumor-
bearing nu/nu mice (static image obtained 4 h PI, 10 min scan). Block with KCRGDC 
on left in both panels. (A) Coronal slice with tumor (T), liver (L), and fiducial (*) 
indicated. (B) Transaxial slice with tumor indicated. 
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Figure 10. Small-animal PET/CT of 64Cu-DOTA-GGRGDS uptake in U87MG tumor-
bearing nu/nu mice (static image obtained 4 h PI, 10 min scan). Block with GRGDS 
on right in both panels. (A) Coronal slice with tumor (T), liver (L), and fiducials (*) 
indicated. (B) Transaxial slice with tumor and fiducial indicated. 
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Figure 11. Standard uptake values for 64Cu-DOTA-RGD peptides in U87MG tumor. 
 
 
 
 
Figure 12. Comparison of post-PET imaging biodistribution in U87MG tumor-bearing 
nu/nu mice (24 h PI) (n = 2).  
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Discussion and Conclusions 
 The goal of this study was to systematically evaluate the affinity, receptor 
specificity, cellular internalization and tumor localization properties of a series of 
structurally diverse RGD peptides. A lactam-cyclized, disulfide-cyclized, and linear 
peptide, as well as a lactam-cyclized control were selected for evaluation. While 
none of these peptides are novel, they have not previously been rigorously studied 
using the same assays to allow for direct comparison of their respective in vitro and 
in vivo properties. The results are useful for the design and evaluation of future 
integrin αvβ3 imaging agents. 
 Peptides were screened against the integrins αvβ5 and αIIbβ3, found on 
macrophages and platelets respectively, to evaluate the specificity of the compounds 
towards the integrin αvβ3. The cyclic lactam c(RGDyK) peptide sequence is known to 
possess high affinity and selectivity for αvβ3 relative to αvβ594; however, it’s high 
affinity for αIIbβ3 was surprising and could contribute to high background in imaging 
studies. The more than five hundred-fold enhancement of binding of KCRGDC 
towards αvβ3 compared with αIIbβ3, and hundred-fold compared to αvβ5, suggests high 
selectivity. The linear peptide has similarly high selectivity, with three hundred-fold 
higher affinity for αvβ5 and fifty-fold higher affinity for αIIbβ3. While αvβ3 is upregulated 
in angiogenesis and other disease processes, integrins αvβ5 and αIIbβ3 are 
upregulated in other disease processes and found on other non-disease cells. Highly 
selective peptide results are promising for application in clinical imaging and 
therapeutic settings. 
 The cell-based assays were performed to evaluate the internalization 
efficiency of the peptides in αvβ3–positive cells. Block experiments performed with an 
excess of non-radiolabeled peptide resulted in significantly lower levels of 
internalization for all peptides studied and is consistent with receptor mediated 
endocytosis of the radiotracer. Additionally, whole cell assays introduce factors not 
present in the isolated receptor binding assays carried out with purified proteins and 
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allowed for confirmation of the receptor specificity of the observed binding. 
Internalization of each of the RGD peptides was observed with varying extents 
 
64Cu-DOTA-KCRGDC > 64Cu-DOTA-GGRGDS ~ 64Cu-DOTA-c(RGDyK). Although 
in the isolated binding assay c(RADyK) showed low affinity for αvβ3, specific, 
blockable cell surface binding was observed. Therefore, this compound will not serve 
as a good negative control in vivo. Investigation of another variant, c(GREyK), which 
has also demonstrated low affinity towards the isolated integrins, is being studied. 
 The U87MG glioblastoma tumor model has been well-established to have a 
high level of integrin αvβ3 expression.143 Tumor uptake and retention of 64Cu-DOTA-
KCRGDC was five to ten times higher than either 64Cu-DOTA-GGRGDS or 64Cu-
DOTA-c(RGDyK). This disparity led to nearly identical tumor:background ratios for 
each compound at all time points. The high tumor:blood ratio for 64Cu-DOTA-
c(RGDyK) combined with the observed ability to block tumor uptake with co-
administration of an excess of unlabeled peptide, suggests that in vivo imaging 
would afford tumor visualization. Chen, et al. reported the use of 64Cu-DOTA-
c(RGDyK) for tumor angiogenesis imaging in MDA-MB-435 tumor-bearing mice.144 
They observed prolonged tumor retention and persistent uptake in the liver, with 
strong contrast from the background tissue in microPET imaging. 
 Attempts to demonstrate that 64Cu-DOTA-KCRGDC and 64Cu-DOTA-
GGRGDS  accumulation in the tumor was receptor specific, were not successful. 
Coadministration of a competitive dose of KCRGDC or GRGDS was ineffective in 
blocking in vivo tumor uptake of 64Cu-DOTA-KCRGDC or 64Cu-DOTA-GGRGDS, 
respectively. The chosen blocking quantity, 18 mg/kg, was based on previous work 
that showed it was sufficient to completely inhibit radiolabeled RGD peptide 
analogues in αvβ3-positive tissue.103, 145 While we observed partial inhibition of 64Cu-
DOTA-c(RGDyK) accumulation, neither 64Cu-DOTA-KCRGDC nor 64Cu-DOTA-
GGRGDS accumulation was inhibited at this dosing level, a thousand-fold excess of 
the administered dose of radiolabeled peptide. While many groups have reported 
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successful in vivo blocking, we are not the first to report difficulty blocking in vivo 
accumulation despite the ability to efficiently block accumulation in vitro.146 The lack 
of competitive inhibition may be due to differing clearance properties between the 
radiolabeled 64Cu-DOTA-peptide and the peptide, extremely rapid recycling of 
integrin αvβ3 following peptide-mediated internalization, or a combination of the 
two.147 
 Small-animal imaging of 64Cu-DOTA-KCRGDC and 64Cu-DOTA-GGRGDS in 
a murine U87MG tumor model demonstrated tumor uptake for both compounds. 
There is good correlation between the observed liver and kidney accumulation by 
microPET and the tissue biodistribution measurements. The images produced with 
the linear peptide, 64Cu-DOTA-GGRGDS, have a noisy, non-uniform distribution 
through the tissues with radiotracer uptake, but the tumor is discernable, aided by 
coregistration with microCT. Neither specific activity nor injected dose has been 
optimized to improve tumor visualization. Previously, it has been reported that the 
linear peptides do not accumulate in tumor and are not clearly visualized in small-
animal imaging148 due to poor in vivo stability.110 While the tumor could be visualized 
with 64Cu-DOTA-GGRGDS on a coregistered PET/CT image, the clarity of the image 
is worse than that of the 64Cu-DOTA-KCRGDC images. Cyclic peptides seem to be 
more resistant to proteolysis, and their conformationally constrained state traps them 
in the active conformation. Thus, cyclization improves tumor targeting efficiency. 
 While the disulfide-cyclized 64Cu-DOTA-KCRGDC exhibits the best in vitro 
behavior, 64Cu-DOTA-c(RGDyK) has better in vivo properties. The benefits of the 
synthetic simplicity afforded by a disulfide-cyclized peptide versus a lactam-cyclized 
one must be weighed against the improved in vivo performance. Future studies with 
new versions of RGD peptide amphiphiles may produce compounds in which these 
properties are not in opposition. 
Further in vivo investigation of the compounds reported upon here is 
warranted to demonstrate targeting specificity of the peptides along with exploration 
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of a different peptide as a negative control. Improved pharmacokinetics of RGD-
peptide based radiopharmaceuticals would also be necessary for successful 
adoption as diagnostic imaging or radiotherapeutic agents. Higher binding affinity is 
being investigated through multimeric peptides and conjugation of several peptides 
onto the surface of nanoparticles. High αvβ3 binding affinity and specificity along with 
good in vivo pharmacokinetics would enable RGD-peptide based 
radiopharmaceuticals to be used for diagnostic imaging and as therapeutic agents 
for cancer and other αvβ3-expressing disease states. 
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CHAPTER 4 
 
Preparation, Purification, and In Vitro Characterization  
of RGD-Functionalized Shell Crosslinked Nanoparticles 
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Abstract 
 In this work, micelles and shell crosslinked nanoparticles (SCKs) prepared 
from poly(acrylic acid)-b-polystyrene (PAA-b-PS) were labeled with the cyclic peptide 
KCRGDC, as nanoscale agents for non-invasive imaging and targeted drug delivery.  
This peptide contains the tripeptide arginine-glycine-aspartic acid (RGD) sequence 
as the recognition motif for the αvβ3 integrin receptor, which is highly expressed in 
areas where angiogenesis occurs.  Methods were developed to afford nanoparticles 
labeled with covalently attached and ready-to-bind KCRGDC peptide.  The binding of 
these peptide-labeled nanoparticles was evaluated by measuring IC50 values to αvβ3.  
In order to specifically target the αvβ3 integrin, selectivity against another integrin, 
αvβ5, was also demonstrated.  The best affinity to αvβ3 was achieved by attaching the 
KCRGDC peptide to the micelle assembled from HOOC-PEG30004.0-g-
DOTAlysine3.2-g-PAA58.2-b-PS71, with IC50 value being 0.49 nM, a significant 
enhancement from that of the KCRGDC, whose IC50 value to αvβ3 is 10.5 nM. These 
materials are of interest for cancer imaging and therapeutic delivery and in vitro cell 
assay experiments should be performed to determine cellular binding and 
internalization. 
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Introduction 
 Angiogenesis is a physiological process involving the growth of new blood 
vessels from existing vasculature.149  It is a normal process involved in many 
biological processes, e.g. embryogenesis, wound healing, and tissue remodeling; 
however, it is also a fundamental step in the transition of tumors from a dormant 
state to a malignant one.  Several disorders are characterized by either an excess or 
insufficient number of blood vessels, e.g. rheumatoid arthritis38, psoriasis150, 
restenosis151, and diabetic retinopathy152.  
 Angiogenesis is a multi-step, invasive process, characterized by endothelial 
cell proliferation, modulation of the extracellular matrix (ECM), and cell 
adhesion/migration.  Among the many angiogenic factors, integrin αvβ3 has been 
found to be necessary for the formation, survival, and maturation of new blood 
vessels.153  In human melanoma cells, the expression of αvβ3 is correlated with 
malignancy grade, collagenase production, and cell growth.154, 155  Due to integrin 
αvβ3’s key role in many physiological processes, it has been evaluated extensively as 
a drug target.  The tripeptide sequence arginine-glycine-aspartic acid (RGD) is 
common to various ECM proteins, e.g. vitronectin, fibronectin, fibrinogen, 
thrombospondin, and von Willebrand factor, involved in cell-matrix adhesion.31, 156  
High-affinity αvβ3 selective ligands containing RGD have been identified by phage 
display.157  Targeted chemotherapy has been investigated using RGD peptides to 
deliver doxorubicin158 and proapoptotic peptides159 to tumor vasculature.  In vivo 
imaging of sites of angiogenesis has been demonstrated using RGD-containing 
peptides.160, 161 
 Since the RGD-sequence is conserved in all native ligands, differences in 
binding affinities and specificity can be obtained from slight modifications.  The 
flanking amino acid residues, especially the two positions following the aspartic acid, 
are known to affect binding affinity both by direct interaction of the residues with the 
integrin as well as influencing peptide folding.156  Cyclization is a common technique 
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to improve binding properties because it confers rigidity on the structure.162  All 
selective RGD peptides have at least one ring structure.  It has been recently 
reported that multimeric RGD peptides can enhance the affinity of the receptor-ligand 
interaction through either multivalent binding or statistical rebinding.  Polyvalency 
affords better targeting capability and higher cellular internalization because of 
increased apparent ligand concentration.163  The unique structural properties of 
nanoscale materials provide the ability for them to carry therapeutic agents and to 
present numerous targeting moieties as well.  Furthermore, multivalency has been 
shown to facilitate internalization.47  Carrier systems like liposomes,164 polymers,165-
167
 nanoparticles,168 and proteins169 bearing multiple RGD peptides are therefore 
more likely to be internalized via receptor-mediated endocytosis than single peptide 
constructs. 
 In this work, the disulfide-cyclized KCRGDC peptide was selected as the 
antagonist to αvβ3, while shell crosslinked nanoparticles (SCKs) were used as the 
carrier system.  SCKs are self-assembled core-shell nanomaterials, originating from 
crosslinking the shell domain of micelles assembled from amphiphilic block 
copolymers, poly(acrylic acid)-b-polystyrene (PAA-b-PS) in this work.  The SCKs 
produced have a robust structure due to the covalent crosslinking reaction, and have 
controllable sizes ranging from 10 to 200 nm.170, 171  SCKs conjugated with KCRGDC 
peptide were synthesized via various methods and were tested for binding affinities 
to αvβ3 via in vitro plate-based assays. Improved binding affinities were achieved, 
compared to the KCRGDC peptide as a small molecule that is capable only of 
monovalent binding. With the enhanced blood circulation times that can be achieved 
by grafting poly(ethylene glycol) from the nanoparticles,172 these multi-functional 
materials could be good candidates as carrier systems for imaging and therapeutic 
agents, selectively to injured or diseased tissues that overexpress αvβ3. 
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Experimental Procedures 
General Materials and Methods. All chemicals were purchased from Sigma-
Aldrich and used without further purification unless otherwise noted.  Nanopure water 
(18 MΩ⋅cm) was acquired by means of a Milli-Q water filtration system (Millipore 
Corp.; Bedford, MA).  KCRGDC was custom synthesized by Tianma Pharma Co., 
Suzhou, China, and used as received.   
Integrin binding assay. An isolated, competitive binding assay described 
previously83, 173 is utilized here.  Briefly, vitronectin (Chemicon CC080) was 
biotinylated with N-hydroxysuccinimide biotin (2 h at room temperature) before 
dialysis into PBS, pH 7.4. The wells of a 96-well plate (Nunc Immuno Plate with 
MaxiSorp) were coated with 100 µg integrin αvβ3 or αvβ5 (Chemicon CC1019 and 
CC1025, respectively) in coating buffer (20 mM Tris, pH 7.4, 150 mM NaCl, 2 mM 
CaCl2, 1 mM MgCl2, 10 µM MnCl2).  The plates were then blocked (1 h at 4 °C) with 
bovine serum albumin (BSA) (3% in coating buffer).  After washing three times with 
binding buffer (0.1% BSA in coating buffer), biotinylated vitronectin (final 
concentration 14 nM) with and without serially diluted ligands was allowed to bind to 
the integrins (3 h at 37 °C). After washing (3 times i n binding buffer), bound 
biotinylated vitronectin was detected by binding ExtrAvidin alkaline phosphatase 
(1/35,000 dilution, 1 h at room temperature) using the p-nitrophenyl phosphate liquid 
substrate system as the chromogen.  Each concentration data point was done in 
triplicate, and each binding experiment was performed at least twice.  Nonlinear 
regression was used to fit binding curves and calculate inhibitory concentrations of 
50% (IC50 value) (Prism, version 5.02; GraphPad). 
 
Results and Discussion 
To create a functional nanomaterial that is capable of carrying imaging and/or 
therapeutic agents to a selective tissue site, it is imperative that the targeting ligand 
be accessible for binding with the receptor target.  Two general approaches, the 
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post-conjugation method and the pre-conjugation method, were, therefore, applied to 
afford micelle/SCK nanoparticles functionalized with a disulfide-cyclized RGD 
peptide, KCRGDC.  For the post-conjugation method, SCK nanoparticles were first 
prepared from the amphiphilic diblock copolymer precursors (PAA-b-PS), according 
to our established protocol, the cyclic KCRGDC peptide or the amine-terminated 
PEO113-5-FAM-KCRGDC were then conjugated onto the nanoparticle shell domain 
through carbodiimide-mediated aqueous amidation  (see Experimental Section for 
details).  For the pre-conjugation method, the PAA-b-PS block copolymers were 
modified with the KCRGDC peptides via amidation chemistry in organic solvent, 
followed by aqueous assembly into nanostructures and crosslinking across the shell 
domain of nanoparticles.172, 174  Coincident with these synthetic efforts were rigorous 
physicochemical studies to determine the composition and structure of the resulting 
materials, and biological evaluations to determine the binding affinities between the 
ligand bound to the nanostructure and receptors either coated on a plate or 
presented on cells.  The synthetic work and physicochemical studies were performed 
by collaborators and details can be found in Appendix III, whereas the biological 
studies were the focus of my studies. 
Integrin Binding Assay. This assay tests the heterologous competitive 
binding to the integrin between biotinylated vitronectin and an RGD peptide or RGD-
SCK construct and allows for calculation of the IC50 value. While the integrin binding 
assay protocol was developed for small molecules and peptides,83 this work 
demonstrates the applicability of this isolated integrin binding assay for nanoparticles 
as well. The specificity of the ligand for αvβ3 is determined by measuring the affinity 
for the integrin αvβ5, which is expressed on macrophages. A peptide of known 
binding affinity, usually KCRGDC, was included as an external reference in each 
assay.  
Post-conjugation of KCRGDC peptide onto micelles and SCKs. The work 
started with post attachment of the KCRGDC peptide onto micelles and SCKs 
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prepared from PAA61-b-PS34 (Scheme 1 and Table 1).  Nanoparticles with varied 
numbers of KCRGDC were prepared by controlling the coupling stoichiometry. 
Determination of the IC50 values for these samples showed that the micelle/SCKs 
with no KCRGDC peptide attached showed no binding to either αvβ3 or αvβ5, at 
concentrations up to 10,000 nM. For KCRGDC-labeled nanoparticles, poor binding 
affinity to αvβ3 was observed for micelles and 20% crosslinked SCKs.  An interesting 
phenomenon is that the KCRGDC-micelle samples showed very good binding to αvβ5 
instead to αvβ3, although KCRGDC has poor binding to αvβ5 as a small molecule. The 
reason behind this phenomenon has not been investigated.  Compared to micelles 
and 20% crosslinked SCKs, enhanced and also selective binding to αvβ3 was 
achieved with 50% crosslinked SCKs.  Also, as the number of peptides per SCK 
increased from less than 1 to c.a. 52, the IC50 value towards αvβ3 improved, 
decreasing from 380 nM to 37.8 nM.  It is hypothesized that as the extent of 
crosslinking increases, more of the peptides attached to the nanoparticle will be 
located on the outer surface of the nanoparticles to be accessible for integrin binding, 
thus improving the nanoparticles’ binding affinities as well.  Increased loading of 
peptides also leads to better binding.   
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Scheme 1.  Illustration of post-labeling KCRGDC peptide to micelle/SCK. 
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Table 1. IC50 values of KCRGDC-micelle/SCKs prepared by post-labeling method. 
Samples Naggr. Peptide per NPa 
Peptide 
per NPb 
IC50 (nM)d 
αvβ3 αvβ5 
KCRGDC    10.5 921 
Micelle 125 0 0 > 10,000 > 10,000 
20% Crosslinked SCK 125 0 0 > 10,000 > 10,000 
50% Crosslinked SCK 125 0 0 > 10,000 > 10,000 
KCRGDC-Micelle 
125 4 n.d.c > 10,000 1.5 
125 40 n.d. > 1,000 0.3 
125 400 n.d. 1,080 26.1 
KCRGDC-SCKs 
20% Crosslinked 
125 4 n.d. > 5,000 > 10,000 
125 40 < 1 > 1,000 > 10,000 
125 400 58 > 1,000 > 5,000 
KCRGDC-SCKs 
50% Crosslinked 
125 4 n.d. > 1,000 > 10,000 
125 40 < 1 380 > 5,000 
125 400 42 37.4 > 10,000 
  
a
 nominal numbers of peptide per nanoparticle (NP) from stoichiometry; b numbers 
of peptide per nanoparticle measured from Ellman’s assay; c not determined; d IC50 
values for micelle/SCKs were measured to be the concentrations of the 
nanoparticles in units of nM. 
 
 
Post-conjugation of NH2-PEG5000-5-FAM-KCRGDC onto PEGylated SCKs 
prepared from mPEG20005.5-g-DOTA-lysine2.5-g-PAA52-b-PS60. Relative to 
KCRGDC, the binding affinity for KCRGDC-labeled nanoparticles to αvβ3 still needed 
to be improved.  Facile ways to achieve this would be to increase the peptide density 
on nanoparticles or to add a spacer between KCRGDC and nanoparticles to make 
the peptide more accessible for binding.  Meanwhile, besides good binding, 
nanoparticles with good biodistribution are also desired.  A well known method to 
achieve improved biodistribution is the introduction of poly(ethylene glycol) (PEG), 
grafted on the surface of particles.172, 175  To achieve this end, 20% and 50% 
crosslinked SCKs prepared from mPEG20005.5-g-DOTA-lysine2.5-g-PAA52-b-PS60 
which were reported to have good blood retention times were selected. The DOTA-
lysine here acts as a chelator for radiometal incorporation for PET imaging. A 
PEGylated KCRGDC peptide, NH2-PEG5000-5-FAM-KCRGDC, was prepared. The 
PEG5000 linker was used to allow the attached peptide to be more accessible for 
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integrin binding, and the fluorophore, 5-FAM, was incorporated for improved 
quantification of the peptide by UV-vis, thereby eliminating the need to perform the 
Ellman’s assay.  Scheme 2 illustrates the coupling reaction and Table 2 shows the 
characterization and binding affinities of samples prepared by this method.   
The coupling efficiency was found to be extremely low (0.6% and 0.4% for 20% 
and 50% crosslinked PEGylated SCKs, respectively).  The layer of poly(ethylene 
glycol) that surrounded the SCKs can cause the low coupling efficiencies by 
hindering access of the PEGylated 5-FAM-KCRGDC to the carboxyl groups in the 
shell of the nanoparticles.  Compared to KCRGDC, both 5-FAM-KCRGDC and 
PEG5000-5-FAM-KCRGDC showed slightly decreased binding affinities to αvβ3.  Due 
to the low peptide coupling, no appreciable binding to αvβ3 was observed for the two 
PEGylated SCKs labeled with PEG5000-5-FAM-KCRGDC. 
 
 
Table 2. IC50 values of PEGylated SCKs, post-conjugated with NH2-PEG5000-5-
FAM-KCRGDC. 
Samples Naggr. Peptide per NPa 
Peptide 
per NPb 
IC50 (nM)c 
αvβ3 αvβ5 
5-FAM-KCRGDC    23.0 > 1,000 
PEG5000-5-FAM-KCRGDC    21.3 > 1,000 
20% Crosslinked PEG-5-
FAM-KCRGDC-SCK 200 1000 6.3 > 1,000 > 10,000 
50% Crosslinked PEG-5-
FAM-KCRGDC-SCK 200 1000 4.2 > 5,000 > 10,000 
a
 targeted number of peptide per nanoparticle based on stoichiometry; b number of 
peptides per nanoparticle as determined by UV-vis (ε(5-FAM-KCRGDC)492nm = 
63,000 M-1cm-1); c IC50 values for micelle/SCKs were measured to be the 
concentrations of the nanoparticles in units of nM. 
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Scheme 2.  Illustration of post-conjugation of NH2-PEO113-5-FAM-KCRGDC onto SCKs prepared from 
mPEG20005.5-g-DOTA-lysine2.5-g-PAA58-b-PS54. 
DOTA 
KCRGDC 
peptide 
PEG
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 Pre-labeling of NH2-PEG5000-5-FAM-KCRGDC onto mPEG20005-g-
DOTA-lysine-g-PAA-b-PS, followed by micelle assembly and crosslinking into 
SCKs. Due to the low peptide coupling efficiencies, NH2-PEG5000-5-FAM-KCRGDC 
was pre-labeled onto mPEG20005-g-DOTA-lysine-g-PAA-b-PS block copolymers, in 
DMF, to achieve better coupling through amidation chemistry facilitated by EDCI and 
HOBt (Scheme 3).  PAA-b-PS block copolymers with composition similar to PAA60-b-
PS60 were used.  TEM images showed that these PEGylated micelle/SCKs were 
spherical nanoparticles with narrow size distributions (Figure 1).  Detailed 
characterization data and IC50 values are provided in Table 3.  Compared to the post-
labeling method, increased amounts of peptide were able to be incorporated onto the 
nanoparticles prepared through the pre-labeling method as a result from the 
increased coupling efficiency for amidation reactions carried out in DMF rather than 
water.   
 
 
 
A B D C 
Figure 1. Transmission electron microscopy (TEM) images of PEGylated 
micelle/SCK nanoparticles, prepared from pre-labeling the NH2-PEG5000-5-FAM-
KCRGDC onto the amphiphilic PAA-b-PS block copolymers.  A, micelle from 
mPEG20002.4-g-DOTA-lysine2.0-g-PEG5000-5-FAM-KCRGDC0.6-g-PAA59-b-PS54; B, 
50% crosslinked SCK from mPEG20002.4-g-DOTAlysine2.0-g-PEG5000-5-FAM-
KCRGDC0.6-g-PAA59-b-PS54; C, micelle from DOTAlysine2.5-g-PEG5000-5-FAM-
KCRGDC0.5-g-PAA65-b-PS70; D, 50% crosslinked SCK from DOTA-lysine2.5-g-
PEG5000-5-FAM-KCRGDC0.5-g-PAA65-b-PS70.  Scale bar 100 nm. 
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Scheme 3.  Graphic representation of the synthesis PEGylated SCKs labeled with KCRGDC peptide by pre-labeling 
NH2-PEO113-5-FAM-KCRGDC onto the SCK precursor, mPEG2000-g-DOTAlysine-g-PAA-b-PS. 
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Initially, nanoparticle samples were purified by dialysis in MWCO 100 kDa 
dialysis tubings to remove non-covalently bound NH2-PEG5000-5-FAM-KCRGDC 
(samples 2-4 in Table 3). The IC50 values of these nanoparticles towards αvβ3 were 
dramatically improved compared to samples prepared by the post-labeling method.  
Unfortunately, fast protein liquid chromatography (FPLC) analysis of these 
nanoparticles clearly showed that a considerable amount of non-covalently attached 
NH2-PEG5000-5-FAM-KCRGDC was present.  Since the shell of the nanoparticles is 
composed of poly(acrylic acid) as well as mPEG2000, which can result in strong van 
der Waals interactions such as hydrogen bonding between the free NH2-PEG5000-5-
FAM-KCRGDC and the shell/surface domain area, it made the complete removal of 
the NH2-PEG5000-5-FAM-KCRGDC by dialysis difficult.   
Centricon tubes (MWCO 10000 Da) were used to remove the free peptide, 
making use of the shear force centifugation provides, but free peptide was still 
present.  These samples were also dialyzed in high salt buffer (samples 6-8), with 
the expectation that high salt concentration decreases the interactions between the 
peptide and the nanoparticles.  After 30 d dialysis, although no free peptide was 
observed by FPLC, the binding affinities of these nanoparticles also decreased.  It’s 
possible that the peptide might have been degraded, causing a loss of activity, 
during the long dialysis.   
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Table 3. Characterization data and IC50 values of micelle/SCK nanoparticles labeled with RGD peptide prepared by pre-labeling the NH2-
PEG5000-5-FAM-KCRGDC onto the amphiphilic PAA-b-PS block copolymers. 
a
 IC50 values for micelle/SCKs were measured to be the concentrations of the nanoparticles in units of nM. 
b
 Limited sample size and concentration enabled a relatively low IC50 valueminimum value for these samples. 
entry Samples Polymer Precursor DTEM Naggr. Purification method Peptide per NP2 
IC50 (nM)a 
x y z m n nm αvβ3 αvβ5 
1 PEG5000-5-FAM-KCRGDC          21.3 > 1,000 
2 PEG5000-5-FAM-KCRGDC-NP (micelle) 2.4 2.0 0.6 64 54 14 ± 2 240 Dialysis in MWCO 100 kDa 
tubing in 5 mM PBS, pH 7.4, for 
4 d 
140 11.7 > 5,000 
3 PEG-5-FAM-KCRGDC-SCK-NP (50% Crosslinked SCK) 2.4 2.0 0.6 64 54 14 ± 2 240 143 29.9 > 5,000 
4 PEG5000-5-FAM-KCRGDC-NP (micelle) 0 2.5 0.5 68 70 19 ± 2 364 Dialysis in MWCO 100 kDa 
tubing in 5 mM PBS, pH 7.4, for 
4 d 
192 65.7 > 5,000 
5 PEG-5-FAM-KCRGDC-SCK-NP (50% Crosslinked SCK) 0 2.5 0.3 68 70 19 ± 2 364 118 71.8 > 5,000 
6 PEG5000-5-FAM-KCRGDC-NP (micelle) 2.4 2.0 0.6 64 54 12 ± 2 140 
Dialysis in MWCO 100 kDa 
tubing in 150 mM PBS, pH 7.6, 
for 30 d 
80 > 1,000 >1,000 
7 PEG-5-FAM-KCRGDC-SCK-NP (20% Crosslinked SCK) 2.4 2.0 0.6 64 54 12 ± 2 140 79 388 >1,000 
8 PEG-5-FAM-KCRGDC-SCK-NP (50% Crosslinked SCK) 2.4 2.0 0.6 64 54 12 ± 2 140 76 > 1,000 >1,000 
9 PEG5000-5-FAM-KCRGDC-NP (micelle) 5.5 2.0 1.6 64 54 12 ± 2 100 
Sephadex ® G75 (superfine) 
SEC column 
158 >170b n.d 
10 PEG-5-FAM-KCRGDC-SCK-NP (50% Crosslinked SCK) 5.5 2.0 1.6 64 54 12 ± 2 100 160 >141
b n.d 
11 PEG5000-5-FAM-KCRGDC-NP (micelle) 0 0 0.9 66 71 12 ± 2 118 
Sephadex ® G75 (superfine) 
SEC column 
104 >148b n.d 
12 PEG-5-FAM-KCRGDC-SCK-NP (50% Crosslinked SCK) 0 0 0.9 66 71 12 ± 2 118 101 >130
b n.d 
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retention time /min retention volume /mL 
B 
A 
C 
not binding to αvβ3 up to 100 nM 
D 
 
Figure 2.  Fast protein liquid chromatography (FPLC) traces of A: control sample of RGD-NP prepared from Pre-
conjugation method and purified by dialysis in 5 mM PBS (pH ~ 7.4) for 4 d; B: NH2-PEO113-5-FAM-KCRGDC; C: 
control sample of RGD-NP prepared from Pre-conjugation method and purified by dialysis in 150 mM PBS (pH ~ 7.4) 
for 30 d; D: sample 2 in Table 3. 
.
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These materials were then purified by SEC columns packed from Sephadex ® 
G75 resin (bead size 20-50 µm, fractionation range 1000-50000 Da (Dextrans)).  
Complete removal of the free peptide was confirmed by FPLC (Figure 2).  Despite 
the fact that pure samples without free peptides were obtained, the binding affinities 
for αvβ3 remain worse than that of the PEGylated RGD peptide. This indicates that 
the majority of the peptides attached to the nanoparticles might be located 
underneath the surface and not available for binding to integrin receptors. 
Post-labeling of KCRGDC to micelles functionalized with –NH-PEG-COOH 
chains, targeting attachment of most of the peptides to the end of the PEG 
chains to achieve better accessibility of the peptides for integrin binding. A 
new method was then developed to afford nanoparticles with KCRGDC attached to 
the outer surface (Scheme 4).  In this method, NH2-PEG3000-COOH was attached 
onto the amphiphilic block copolymer first.  The product polymer was then 
assembled into micelles, with some of the PEG-COOH chains expected to spread 
out on the surface of micelles.  The peptide, 5-FAM-KCRGDC was then conjugated 
to the micelles by methods described above.  Crosslinking the shell domain with 2,2’-
(ethylenedioxy)bis(ethylamine) afforded the SCKs.  One micelle and one 50% 
crosslinked SCK were prepared by this method.  IC50 values to αvβ3 were measured, 
as shown in Table 4.  Compared to 5-FAM-KCRGDC, whose IC50 for αvβ3 is 23.0 nM, 
greatly enhanced bindings to αvβ3 were found with the micelle and SCKs, whose IC50 
values were determined to be 1.38 nM and 0.49 nM, respectively. 
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Scheme 4.  Graphic representation of the synthesis KCRGDC-labeled micelles and SCKs by post-labeling 5-FAM-KCRGDC onto micelles 
with PEG-COOH functionalities. 
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Table 4.  Characterization data and IC50 values of 5-FAM-KCRGDC-labeled 
nanoparticles by post-labeling KCRGDC onto micelles with PEG-COOH on the surface. 
entry Samples DTEM Naggr. Purification method 
Peptide 
per NP2 
IC50 (nM)a 
nm αvβ3 
13 Micelle-5-FAM-KCRGD 26 ± 3 825 Sephadex ® 
G75 
(superfine) 
SEC column 
170 1.38 
14 SCK-5-FAM-KCRGD (50% crosslnked) 26 ± 3 825 170 0.49 
a
 IC50 values for micelle/SCKs were measured to be the concentrations of the 
nanoparticles in units of nM. 
 
Conclusions 
 Methods to develop shell crosslinked nanoparticles bearing cyclic KCRGDC 
peptide as the nanoscale antagonist to αvβ3 integrin were described in this study.  
Nanoparticles labeled with KCRGDC prepared from post-labeling the 5-FAM-KCRGDC 
peptide onto micelle/SCKs assembled from HOOC-PEG30004.0-g-DOTA-lysine3.2-g-
PAA58.8-b-PS71 showed much better binding affinities to αvβ3 than those nanoparticles 
prepared from pre-labeling the NH2-PEG5000-5-FAM-KCRGDC to amphiphilic PAA-b-
PS block copolymers.  It is hypothesized that when the NH2-PEG5000-5-FAM-KCRGDC 
was pre-attached to the polymer, the majority of the peptide is buried underneath the 
shell layer during the course of self-assembly, leading to low accessibility to bind to 
outside integrins.  With good integrin αvβ3 binding affinity and selectivity, good 
biodistribution which has been reported172, as well as with the DOTA-lysine serving as 
the chelator of radiometals for imaging for PET imaging, these nanoparticles possess 
potential to be developed into nanoscale diagnostic and therapeutic agent delivery 
vehicles.  
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CHAPTER 5 
 
Concluding Remarks and Future Directions 
  
98 
Radiolabeled receptor-binding peptides have emerged as an important class of 
radiopharmaceuticals for diagnostic imaging and cancer therapy.176 Following 
radionuclide labeling the specific receptor-binding properties of the ligand can be 
exploited to guide the radioactivity to tissues expressing a particular receptor. This 
dissertation reports on the development of integrin αvβ3–targeting radiopharmaceuticals 
for medical imaging applications from the perspective of both the radiometal-labeled 
chelator as well as the targeting peptide. Several macrocyclic copper(II) chelators have 
been studied with the goal of improving kinetic and in vivo stability. Structurally diverse 
bifunctional RGD (arginine-glycine-aspartic acid) peptides were investigated for αvβ3 
integrin affinity in vitro and in vivo. The goal of accomplishing higher binding affinity 
through multivalency has been pursued by evaluating the binding affinity of 
nanoparticles presenting multiple peptides on their surface. 
Copper radionuclides have been the subject of considerable research effort 
because they offer a varying range of half-lives and positron energies, making them 
useful for diagnostic imaging and/or targeted radiotherapy. Ensuring the stability of metal 
complexes in vivo remains a challenge in the development of radiometal-based 
radiopharmaceuticals and significant research effort has been devoted to the 
development of ligands which can stably chelate copper isotopes.57, 177 To design cross-
bridged chelators that complex Cu(II) with faster kinetics while retaining the high in vivo 
stability of CB-TE2A, different ring sizes of cross-bridged tetraazamacrocycles were 
designed. Optimal radiolabeling conditions were established for the 64Cu-labeled 
radiometal chelators, and their in vivo biodistribution and metabolism was studied in 
normal rats. First, a dicarboxylate analog of Springborg’s trimethylene-cross-bridged 
cyclen64, 4,10-bis-(carboxymethyl)-1,4,7,10-tetrazazabicyclo[5.5.3]pentadecane (C3B-
DO2A), exhibited high in vitro stability, which unfortunatly did not translate to high in vivo 
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stability. A two-carbon cross-bridged dicarboxylate analog of homocyclen, 4,11-bis-
(carboxymethyl)-(1,4,8,11-tetraazabicyclo[6.5.2]pentadecane (CB-TR2A), has the same 
ring sizes as C3B-DO2A arranged in a different conformation. This compound did not 
have the same high in vitro stability as Cu-C3B-DO2A, but had better in vivo stability. 
The triazaamacrocyclic chelator 1,4,7-triazacyclononane-N,N’,N’’-triacetic acid (NOTA) 
has been used in radiopharmaceuticals with suggested high in vivo kinetic stability.66, 178 
No study of the Cu-chelator complex alone has been reported in the literature, so the 
stability of 64Cu-NOTA was studied.  
Previously in vitro inertness of copper chelators has been investigated as a 
convenient indicator of in vivo stability,77 but this did not hold for the Cu-chelators studied 
here. Many parameters control the behavior of radiopharmaceuticals in biological media, 
and some of them cannot be easily predicted, requiring in vivo studies. The in vivo 
stability of these complexes could be further evaluated by examination of the 
radiometabolites and determination of the extent of transchelation to proteins. 
Furthermore, a macrocyclic chelator with rapid complexation kinetics which also 
demonstrates kinetic inertness comparable to the previously studied 64Cu-CB-TE2A 
under physiological conditions has not yet been identified. Research in developing Cu(II) 
chelators with even greater stability is clearly warranted. 
Integrin αvβ3 is upregulated in tumor vasculature, osteoclasts, and areas of 
collateral circulation following ischemic injury.28 A series of structurally diverse 
bifunctional RGD (arginine-glycine-aspartic acid) peptides were investigated for αvβ3 
affinity in vitro and in vivo—lactam-cyclized, disulfide-cyclized, and linear RGD 
derivatives and a lactam-cyclized control peptide. The RGD-peptides and the control 
RAD-peptide were screened for integrin αvβ3 binding affinity and specificity compared to 
αvβ5 and αIIbβ3 in a competitive binding assay with each integrin’s native ligand. A 
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lactam-cyclized peptide (c(RGDyK)) demonstrated higher affinity for αvβ3 than disulfide-
cyclized (KCRGDC) or linear peptide (GRGDS). Disulfide-cyclized peptides exhibit the 
best selectivity of the ligands investigated. A control, lactam-cyclized peptide (c(RADyK)) 
has low affinity for all three integrins. Extent of internalization of the 64Cu-DOTA-peptides 
in αvβ3-positive U87MG human glioblastoma cells was determined. Uptake of RGD 
peptides could be blocked by high doses of unlabeled peptide. Internalization of the 
control peptide was minimal, although specific surface binding was observed. Disulfide-
linked KCRGDC exhibited the best in vitro behavior—binding affinity, selectivity, and 
internalization.  
Biodistribution studies of the three 64Cu-DOTA-RGD peptides in U87MG tumor-
bearing nu/nu mice showed rapid uptake and retention of the 64Cu-labeled peptides in 
tumor with good tumor:blood and tumor:muscle ratios. At 4 h post-injection tumor:muscle 
ratios for all three compounds were similar, but 64Cu-DOTA-c(RGDyK) had a significantly 
higher tumor:blood ratio (p< 0.001). Uptake of 64Cu-DOTA-c(RGDyK) can be blocked by 
co-administration of high doses of unlabeled peptide. Blocking of 64Cu-DOTA-KCRGDC 
and 64Cu-DOTA-GGRGDS uptake at 1 h was not attained with either co-injection or pre-
injection (15 min or 1 h) of cold peptide. Further in vivo investigation is warranted to 
demonstrate targeting specificity of the peptides along with investigation of a different 
peptide as a negative control.  
Polyvalency is known to have a profound effect on receptor-binding affinity and in 
vivo kinetics of radiolabeled multimers. The goal of accomplishing higher binding affinity 
through multivalency has been pursued by evaluating the binding affinity of SCK 
nanoparticles presenting multiple RGD peptides on their surface. Micelles and shell 
crosslinked nanoparticles (SCKs) prepared from poly(acrylic acid)-b-polystyrene (PAA-b-
PS) were labeled with the disulfide-cyclized peptide KCRGDC and studied as nanoscale 
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agents for non-invasive imaging and targeted drug delivery. The SCKs produced have a 
robust structure due to the covalent crosslinking reaction and have controllable sizes 
ranging from 10 to 200 nm.179 Difficulties encountered in obtaining nanoparticles with 
high levels of bioavailable radiometal macrocyclic chelator and targeting peptide on the 
surface led to a systematic study of methods of shell functionalization and particle 
purification with chemical, physical, and biological evaluation of each compound. With 
the good cell targeting capabilities, good biodistribution been reported,172 as well as with 
the DOTA-lysine acting as the chelator of radiometals for imaging for PET imaging, 
these nanoparticles possess good potential to be developed into nanoscale diagnostic 
and therapeutic agent delivery vehicles. 
The development of radiometal-labeled peptides is a relatively slow process, thus 
in this work optimization of various aspects was studied in parallel. This dissertation 
contains many disappointing results, but the data are very relevant in that they suggest 
different properties of chelator structure-activity to consider in future designs and new 
directions in the synthesis and characterization of nanoparticles for targeted imaging and 
drug delivery. Each chapter presents a small contribution, but the knowledge gained 
from these studies can be taken together to produce radiopharmaceuticals with optimal 
properties—high in vivo stability, high target uptake with low uptake in non-target 
tissues, and rapid blood clearance preferably through renal excretion. 
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APPENDIX I 
 
Chapter 2 Supplemental Information 
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Experimental Section 
 Collaborators. The experimental procedures for work related to Chapter 2 but 
performed by collaborators are included here. Synthesis of C3B-DO2A was performed 
by Dr. Riccardo Ferdani, CB-TR2A by Yijie Peng (University of New Hampshire, 
Durham, NH)75 and NOTA by Elizabeth Garcia (UNH). Synthesis of all natCu(II)-chelator 
complexes and their characterization was carried out at UNH in the laboratory of Dr. Ed 
Wong. The Cu-CB-TR2A work has been reported in the doctoral dissertation of 
Antoinette Odeendaal (UNH).76 X-ray crystallography was done in the laboratory of Dr. 
Arnold Rheingold at the University of California—San Diego (La Jolla, CA); Cu-CB-TR2A 
structure solved by James Golen. Dr. Thad Wadas was responsible for radiochemistry 
involving CB-TR2A. 
 Materials and methods. Unless otherwise specified all chemicals were 
purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO) and used as received. 
Cyclen was purchased from Macrocyclics (Dallas, TX). Copper chloride (CuCl2) was 
purchased from Johnson Matthey (West Deptford, NJ). All solutions were prepared using 
water which had been distilled and then deionized (18 MΩ/cm2) by passing through a 
Milli-Q water filtration system (Millipore Corp., Bedford, MA). 
 Infrared spectra were obtained as KBr pellets on a Nicolet MX-1 FTIR 
spectrophotometer. Electronic spectra were recorded on a Carey 50 Bio UV/Vis 
spectrophotometer. NMR spectra were taken using a Varian 300 MHz instrument and 
referenced against internal trimethylsilane. ES-MS was accomplished using a Waters 
Micromass ZQ (Millford, MA). Elemental analyses were carried out by Galbraith 
Laboratories, Inc. (Knoxville, TN). 
  
104 
 Synthesis of C3B-DO2A. CB3-DO2A (5) was synthesized according to the 
scheme shown in Scheme 1. Note that compound 3 was synthesized according to a 
procedure previously published by Springborg et al. in 1995.65  
 
 pyridine
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Scheme 1. Synthesis of CB3-DO2A. 
 
Briefly, cyclen was treated with 2 equivalents of p-toluene-sulfonyl chloride (TsCl) in 
pyridine: the only product obtained was the 1,7-bis- tosylated derivative 1. The 3-carbon 
cross bridge was then introduced by alkylation of the 2 secondary nitrogen atoms with 1 
equivalent of 1,3-propanediol di-p-tosylate. Compound 2 was used in the following step 
with no further purification: the protecting tosyl groups were removed upon refluxing 2 in 
a HBr/CH3COOH mixture for 3 days. Recrystallization of the crude product yielded 
compound 3 that was alkylated with 2 equivalents of tert-butyl bromoacetate. The final 
product was obtained by removing the tert-butyl protecting groups in TFA/CH2Cl2. 
 4,10-bis-(carbo-tert-butoxymethyl)-1,4,7,10-
tetrazazabicyclo[5.5.3]pentadecane (4). Compound 3*3HBr (0.45 g, 1.0 mmol) was 
dissolved in acetonitrile (25 mL) and then Na2CO3 (0.45g, 4.2 mmol) and tert-butyl 
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bromoacetate (0.34 mL, 2.3 mmol) were added and the reaction was heated to 60 °C for 
3 days. After cooling, the solid was filtered off and the solution was evaporated under 
reduced pressure. The crude was dried at the high vacuum pump and then triturated 
with ethyl ether to give 4 in a 95% yield. 1H-NMR (DMSO-d6, 300 MHz): δ 1.32 (s, 18H, 
C(CH3)3), 1.68 (m, 2H, NCH2CH2CH2N), 2.65-3.05 (m, 20H, NCH2CH2N and 
NCH2CH2CH2N), 3.38 (s, 4H, NCH2C(O)). 13C NMR (DMSO-d6, 75 MHz): δ 21.4, 28.5, 
50.2, 53.3, 54.1, 55.8, 81.0, 171.4. MS (ESI+): m/z 441.1 (MH+), 385.1 (MH+- 1tBu), 
329.1 (MH+- 2tBu).  
 4,10-bis-(carboxymethyl)-1,4,7,10-tetrazazabicyclo[5.5.3]pentadecane (5). 
Compound 4 (0.47 g, 1.1 mmol) was dissolved in a 1:1 mixture of dichloromethane (15 
mL) and trifluoroacetic acid (15 mL) and the reaction was stirred at room temperature 
under argon for 3 days. The solvent was then evaporated and the remaining oil was 
dissolved in ethanol and slowly precipitated with ethyl ether. The final compound, CB3-
DO2A (5) was obtained, after drying at the high vacuum pump) as a slightly off-white 
solid in a 98% yield. 1H-NMR (D2O, 300 MHz): δ 1.82 (m, 2H, NCH2CH2CH2N), 2.95-
3.25 (m, 20H, NCH2CH2N and NCH2CH2CH2N), 3.61 (s, 4H, NCH2C(O)). 13C NMR (D2O, 
75 MHz): δ 18.2, 51.7, 53.8, 53.9, 60.2, 173.1. MS (ESI+): m/z 329.1 (MH+). Elem. 
analysis: calcd for C15H28N4O4*1.4 NaCl: C 43.92, H 6.88, N 13.64; found: C 43.94, H 
6.92, N 13.30. 
 Synthesis of Cu-C3B-DO2A. An amount of 100 mg (0.203 mmol) of the ligand 
(5) as a trifluoroacetate salt was combined with 75 mg (0.203 mmol) of Cu(ClO4)2•6H2O 
in 8 mL of 95% ethanol. The pH was adjusted to 8.5 with 0.1 N NaOH. The suspension 
was refluxed under nitrogen for 24 h to give a dark blue solution. After thorough removal 
of volatiles under reduced pressure, a dark-blue sticky solid was obtained. This was 
extracted with 4 mL methanol and centrifuged. The supernatant was then placed in vials 
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inside a glass container for diethylether diffusion. A total crop of 75 mg of dendritic dark-
blue crystals formed. Elem. analysis: calcd for C15CuH26N4O4•1.33NaClO4•1.33H2O: C 
31.24, H 5.01, N 9.71, Cl 8.18%. Found: C 31.05, H 5.21, N 9.45, Cl 8.06%. Electronic 
spectrum (aq.) λmax 614 nm (ε = 84.6 M-1cm-1). FT-IR (KBr) νCOO 1687, 1616 cm-1. X-ray 
crystals were grown from a hexafluoro-i-propanol solution upon diethylether diffusion. 
 Synthesis of CB-TR2A. The 4,11-bis(carbo-tert-butoxymethyl)-1,4,8,11-
tetraazabicyclo[6.5.2]pentadecane was prepared from homocyclen according to the 
procedure of Peng (Scheme 2).75, 180 
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Scheme 2. Synthesis of CB-TR2A.75 
 
 Synthesis of Cu-CB-TR2A.76 A solution of 4,11-bis(carbo-tert-butoxymethyl)-
1,4,8,11-tetraazabicyclo[6.5.2]pentadecane (96.0 mg, 0.2179 mmol) in trifluoroacetic 
acid (3.4 mL, 0.046 mol) and CH2Cl2 (3.4 mL) was stirred under N2 for 2 days. The 
reaction mixture was then concentrated under aspirator pressure and the residual 
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solvent was removed under vacuum to give 0.1635 g (0.2179 mol, 100%) of CB-TR2A 
as a brown oil containing 3.7 equivalents of TFA by mass. To the solution of CB-
TR2A•3.7 TFA in 95% EtOH (15 mL) was added Cu(ClO4)2•6H20 (135.5 mg, 0.3657 
mmol) and the pH of the reaction mixture was adjusted to 8 with 1 M NaOH. The 
reaction was then refluxed under N2 for approximately 23 hours. The reaction mixture 
was centrifuged and the supernatant collected and concentrated down under aspirator 
pressure. Residual solvent was removed under vacuum to give 263.7 mg of a blue solid. 
The solid was dissolved in 95% EtOH (15 mL) and the blue solution was placed in a 
diethylether diffusion chamber. A powdery blue solid was collected to give 55.3 mg 
(44%) of Cu•CB-TR2A•2(H20)•1.2(NaClO4). Elem. analysis: calcd for Cu(C15H26N4O4)• 
2(H20)•1.2NaClO4: C, 31.45; H, 5.28; N, 9.78; Cl, 7.43. Found C, 31.49; H, 5.14, N, 9.68, 
Cl, 7.10; IR (KBr) 3536, 3490, 3430, 3394, 3364, 1610, 1485, 1437, 1397, 1320, 1098, 
631 cm-1.  UV-Vis (H20) λmax 608 (ε = 32.1 M-1cm-1); Cyclic voltammetry conducted in 0.1 
sodium acetate: indicated a quasi-reversible reduction with Eρ = -0.950 V (Ag/AgCl). A 
0.13 M solution of Cu•CB-TR2A•2(H20)•1.2(NaClO4) in 95% EtOH was placed in a 
diethylether diffusion chamber. Plate-like blue crystals were collected for X-ray structural 
analysis, which yielded an empirical formula of Cu•CB-TR2A•H20•NaClO4.  
 Synthesis of NOTA. Pendant arming of 1,4,7-Triazacyclononane (TACN) was 
achieved by using adapted  procedure of functionalization of cross-bridged cyclams.181 
Then, the elimination of t-butyl groups was carried out with approximately 600 
equivalents of trifluoroacetic acid (TFA) (Scheme 3). 
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Scheme 3. Synthesis of NOTA. 
 
1,4,7-Triazacyclononane-1,4,7-tri-tertbutylacetate. Compound 3 (0.113 g, 
0.875 mmol) was dissolved in MeCN (4.0 mL). Anhydrous Na2CO3 (0.283 g, 2,67 mmol) 
and t-butyl bromoacetate(0.509 g, 2.61 mmol) were added sequentially to the solution. 
The mixture was heated and stirred under N2 at 50 °C for 24 h. Then, solvent was 
removed and the yellow residue was dissolved in cold solution of 20 % aq NaOH (30 
mL). Keeping an ice bath temperature below 5 °C, solution extractions with cold CHCl3 
(3× 50 mL), organic layers were collected and dried with NaSO4. Chloroform was 
removed to give (0.308 g, 75%). 1H NMR (400 mHz, CDCl3; TMS): δH 3.33(6H, s), 
2.87(12H, s), 1.45(27H, s). 
1,4,7-Triazacyclononane-1,4,7-tri-acetic acid. Compound 8 (0.308 g, 
0.653mmol) was dissolved in TFA (29 mL) and reflux for 24 hours under N2. The solution 
was concentrated to gave brownish crude (0.446 g) which was then triturated with Et2O 
(2× 50 mL). Evaporation of Et2O produced yellow brownish solid (0.390 g). Final product 
was dissolved in warm MeOH (20 mL) and then cooling down to room temperature 
allowed the precipitation of white crystals. 1H NMR (400 mHz, D2O; MeCN): δH 3.35 (6H, 
s), 3.40 (12H, s); 13C{1H} NMR (500 mHz, D2O; MeCH): δC 173.5 (CCarbonyl) , 58.14 
(C1(Ethylene)), 50.96 (C2(Ethylene)). 
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 Synthesis of Na[Cu-NOTA]. This compound was synthesized by a modified 
version of the method reported by Wieghardt et al. in 1982.72 An amount of 0.16 mmol of 
NOTA (as the trifluoroacetate salt) and an equimolar amount of CuCl2•2H2O (28 mg) 
was dissolved in 0.40 mL water. The solution pH was adjusted to neutral using 0.1N 
NaOH, followed by addition of 1 mL of ethanol. After cooling overnight at 0°C, light-blue 
crystals formed.  
 Acid-decomplexation studies. The acid inertness assay was carried out for 
each of the Cu(II)-ligand complexes, according to previously published methods.77 
Briefly, a cuvette containing a sample of the complex in aqueous HCl was monitored by 
its time-dependent electronic spectrum in a Cary 50 spectrophotometer. Cu-C3B-DO2A 
was found to be inert to 5 M HCl at both 60 °C and 9 0 °C for at least one day. In 12 M 
HCl at 90 °C, it decomplexed with a pseudo-first order half life of 7.2(7) days. Cu-CB-
TR2A was determined to have a half-life of 10.8(4) h in 5 M HCl at 30 °C. Cu-NOTA was 
found to be inert to 1 M HCl at both 30 °C and 60 ° C for at least one day but 
decomplexed within minutes in 5 M HCl at 30 °C. 
 Electrochemical studies. This assay was carried out for each of the Cu(II)-
ligand complexes, according to previously published methods.77 Briefly, a 3 mM solution 
of the complex in 0.1 N NaOAc was examined in a BAS 100B Electrochemical Analyzer 
using a glassy carbon working electrode, a platinum wire auxiliary electrode, and a 
Ag/AgCl reference electrode. CV sweeps were performed at 200 mV/s. For Cu-C3B-
DO2A an irreversible reduction peak was observed at ~ -1.03 V with a large copper 
stripping peak upon reoxidation. A quasi-reversible reduction was seen at -0.95 V for 
Cu-CB-TR2A. For Cu-NOTA irreversible reduction peaks were observed at ~ -0.9 and  
-1.2 V along with a large copper stripping peak upon return scanning. 
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 Preparation of 64Cu-CB-TR2A. Preparation of this compound was similar to 
radiolabeling conditions for CB-TE2A.62, 79 To a 1.5 mL acid washed conical vial, was 
added CB-TR2A (100 µL of a 17 mM solution in ETOH), 150 µL of absolute EtOH and 
excess Cs2CO3. This solution was heated at 98 °C for 2-3 h. After cooling and 
centrifugation, 64CuCl2 was added (10 mCi, 2.5 mCi/µL). The solution was sealed, 
vortexed, and incubated for 2 h with shaking at 98 °C . After cooling, radio-TLC was 
performed on regular silica plates with an eluent mixture of 1:1 MeOH:10%NH4OAc. 
Once 95+% was achieved, the supernatant was placed in a second 1.5 mL centrifuge 
tube and heated to reduce the volume of EtOH. When the volume was reduced by 75%, 
200 µL of NH4OAC (pH 7, 0.1 mM) was added to the remaining liquid and the resulting 
solution was mixed and heated again for 15 minutes to remove any remaining EtOH. 
The sample was again re-analyzed using the same TLC conditions. 
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Experimental Procedures 
 Collaborators. The experimental procedures for work related to Chapter 3 but 
performed by Yunpeng Ye are included here. Cells were cultured by Susan Adams and 
Alex Zheleznyak. All cell implants and animal dissections were performed by Chris 
Sherman. Small-animal imaging and post-imaging animal dissections were performed by 
the Radiological Sciences Small Animal Imaging Facility staff. 
 Cyclo[Asp(OBut)-DTry(But)-Lys-Arg(Pbf)-Gly]. The resin-bound protected 
peptide (H-Asp(OBut)-DTyr(But)-Lys-Arg(Pbf)-Gly-resin) was assembled manually from 
H-Gly-2-chlorotrityl resin (1.0 g, 0.54 mmol/g) via Fmoc chemistry as described above. 
The linear protected peptide H-Asp(OBut)-DTyr(But)-Lys-Arg(Pbf)-Gly-OH was cleaved 
by mixing the resin with 1% TFA in dichloromethane (DCM) for 2 min. The filtrate was 
added to a solution of pyridine (5 mL) / methanol (10 mL) and the resin was washed with 
methanol (1x) and dichloromethane (3x). This cleavage procedure was repeated for 5 
times. The combined filtrate was concentrated by evaporation. The product was 
precipitated by adding water (100 mL) and collected by filtration. The linear peptide was 
dissolved in DMF (20 mL) and added drop-wise into a solution of benzotriazole-1-yl-oxy-
tris-pyrrolidino-phosphonium hexafluorophosphate (PyBOP, 520 mg, 1.0 mmol), HOBT 
(135 mg, 1.0 mmol), and DIEA (260 mg, 2.0 mmol) in DMF (80 mL) / DCM (720 mL). 
The mixture was stirred overnight, concentrated, and washed with water to give the 
crude product cyclo[Asp(OBut)-DTyr(But)-Lys(Dde)-Arg(Pbf)-Gly] (ES-MS: [MH]+ 
1148.3). The solid was dissolved in methanol (50 mL), followed by adding hydrazine (1 
mL). The mixture was stirred for 15 min, concentrated, washed with water, and dried. 
The product, cyclo[Asp(OBut)-DTyr(But)-Lys-Arg(Pbf)-Gly], was further purified by flash 
column chromatography to afford the desired compound (320 mg, 60% yield) ES-MS: 
[MH]+ 984.5.  
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 Cyclo[DTyr-Lys(DOTA)-Arg-Gly-Asp]. A mixture of tri-tert-butyl N’,N’’,N’’’,N’’’’-
dodecyltetraacetic acid (DOTA-(3OBut)-COOH) (114.6 mg, 0.2 mmol), the protecting 
cyclic RGD obtained above (98.5 mg, 0.1 mmol), DIC (50.4 mg, 0.4 mmol), and HOBT 
(27.0 mg, 0.2 mmol) was stirred in anhydrous DMF (5 mL) for 8 h and  concentrated 
under high vacuum. ES-MS confirmed the formation of DOTA-RGD peptide conjugation 
([MH]+/[MH2]2+: 1538.7 / 770.4). The residue was dissolved in 4 mL of TFA/water (95 %) 
and kept at room temperature for about 3h and the solution was concentrated. This step 
was repeated for another time. Half of the crude product was purified by semi-
preparative HPLC. The desired fractions identified by ES-MS were combined and 
lyophilized to afford the title compound (31 mg, ~40% yield).  ES-MS: [MH2]2+ 503.7. 
 DOTA-Lys-cyclo(Cys-Arg-Gly-Asp-Cys)-NH2. The resin-bound protected 
peptide Fmoc-Lys(Boc)-Cys(Acm)-Arg(Pbf)-Gly-Asp(OBut)-Cys(Acm)-NH-Rink amide 
resin was assembled manually from Fmoc-Rink amide resin (0.2 g, ~0.20 mmol/g) as 
described above.  Thallium trifluoroacetate (2 equiv) in DMF (5 mL) was added and the 
mixture was swirled for 1.5 h. The resin was washed with methanol (2x) and DMF (3x). 
The resin was swirled with piperidine in DMF (20 %) and washed with methanol (2x) and 
DMF (5x). A mixture of DOTA(3OBut)-COOH (3 equiv), HOBT (3 equiv), and DIC (9 
equiv) in DMF was added into the resin and swirled overnight. The mixture was filtrated 
and washed with DMF (2x) and methanol (3x). The resin obtained was mixed with 
TFA/water (95:5, 3 mL) for 2 and filtered. This step was repeated for another 3 times. 
The filtrate was combined and concentrated to give the crude product. Similarly, HPLC 
purification followed by both ES-MS and analytical HPLC identifications gave the title 
compound (13 mg, ~20% yield).  ES-MS: [MH2]2+  532.6. 
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Experimental Procedures 
Collaborators. All nanoparticles were synthesized by Zicheng Li from polymer 
precursors synthesized by Jinqi Xu, Andreas Nyström, Guorong Sun, and Zicheng Li in 
the laboratory of Dr. Karen L. Wooley. Yongjian Liu, Aviv Hagooly and Tetsuya Mori 
assisted with FPLC analysis. Mike G. Veith assisted with TEM imaging using the 
facilities of the Department of Otolaryngology at Washington University in St. Louis.  
General Materials and Methods. Nitrogen (99.99%) was used for polymerization.  
All chemicals were purchased from Sigma-Aldrich and used without further purification 
unless otherwise noted.  Prior to use, styrene (St; 99%) and t-butyl acrylate (t-BA; 98%), 
purchased from Aldrich, were distilled over calcium hydride.  N,N,N′,N′,N′′-
pentamethyldiethylenetriamine (PMDETA; 99%), ethyl-2-bromopropionate (99%), 
copper(I) bromide (99.999%; Aldrich), trifluoroacetic acid (TFA; 95%), 2,2′-
(ethylenedioxy)-bis(ethylamine) (97%), 1-(3′-dimethylaminopropyl)-3-ethylcarbo-diimide 
methiodide (EDCI; 98%), palladium on carbon (10 wt% loading), N-hydroxysuccinimide 
(NHS; 98%), N-Hydroxysulfosuccinimide sodium salt (sulfo-NHS; 98.5), N,N′-
Dicyclohexylcarbodiimide (DCC; 99%), Succinic anhydride (99%), were used as 
received.  Supor 25 mm 0.1 µm Spectra/Por Membrane tubes (molecular weight cutoff 
(MWCO) 3,500 or 6-8000 Da), purchased from Spectrum Medical Industries Inc., were 
used for dialysis.  Nanopure water (18 MΩ⋅cm) was acquired by means of a Milli-Q water 
filtration system (Millipore Corp.; Bedford, MA).  KCRGDC was custom synthesized by 
Tianma Pharma Co., Suzhou, China, and used as received.  5-FAM-KCRGDC was 
custom synthesized by Chengdu Kaijie Biopharmaceuticals Co. Ltd., Chengdu, China, 
and was used as received. Poly(ethylene glycol) (PEG) and derivatives were purchased 
from Rapp Polymere GmbH, Germany.  Superfine Sephadex ® G75 resin (bead 
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diameter: 20-50 µm; Fractionation range: 1000-50000 Da (Dextrans)) was purchased 
from GE Healthcare and was used to purify aqueous nanoparticle samples. 
1H NMR spectra were recorded on a Varian 300 MHz spectrometer interfaced to a 
UNIX computer using Mercury software.  Chemical shifts are referred to the solvent 
proton resonance.  Infrared spectra were acquired on a Perkin-Elmer Spectrum BX FT-
IR instrument using KBr pellets. 
Absolute molecular weight and molecular weight distribution were determined by 
Gel Permeation Chromatography (GPC). GPC was performed on a Waters 1515 HPLC 
system (Waters Chromatography Inc., Medford, MA), equipped with a Waters 2414 
differential refractometer, a PD2020 dual-angle (15° and 90°) light scattering detector 
(Precision Detector, Inc.), and a three-column series PL gel 5 µm Mixed columns 
(Polymer Laboratories Inc.).  The system was equilibrated at 35 °C in anhydrous THF, 
which served as the polymer solvent and eluent (flow rate set to 1.00 mL/min then 
determined gravimetrically).  All instrumental calibrations were conducted using a series 
of nearly monodispersed polystyrene standards.  Data were collected upon an injection 
of a 200 µL of polymer solution in THF (ca. 5.0 mg/mL), and then analyzed using 
Discovery 32 software (Version, Precision Detectors Inc).  Inter-detector delay volume 
and the light scattering detector calibration constant were determined by calibration 
using a nearly monodispersed polystyrene standard (Pressure Chemical Co., Mp = 90 
kDa, Mw/Mn < 1.04).  The differential refractometer was calibrated with standard 
polystyrene reference material (SRM 706 NIST), of known specific refractive index 
increment dn/dc (0.184 mL/g).  The dn/dc values of the analyzed polymers were then 
determined from the differential refractometer response. 
Differential scanning calorimetry (DSC) measurements were performed with a 
DSC822e instrument (Mettler-Toledo, Inc.) in a temperature range of -100 to 180 °C with 
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a ramp rate of 10 °C/min under nitrogen.  Data were  acquired and analyzed using 
STARe software (Mettler-Toledo, Inc.).  The glass transition temperature, Tg, was 
determined at the midpoint of the inflection tangent upon the third heating scan. 
Samples for transmission electron microscopy (TEM) measurements were diluted 
with 1 wt% of phosphotungstic acid (PTA) stain solution (v/v, 1:1).  Carbon grids were 
exposed to oxygen plasma treatment to increase the surface hydrophilicity.  Micrographs 
were collected at 100,000 magnifications.  The number average particle diameters (Dav) 
and standard deviations were generated from the analysis of a minimum of 150 particles 
from at least three different micrographs. 
The average heights for the nanoparticles were determined by performing 
tapping-mode AFM under ambient conditions in air.  The AFM instrumentation consisted 
of a Nanoscope III BioScope system (Digital Instruments, Veeco Metrology Group; 
Santa Barbara, CA) and standard silicon tips (type, OTESPA-70; L, 160 µm; normal 
spring constant, 50 N/m; resonance frequency, 246-282 kHz).  Samples for AFM 
imaging analysis were prepared through spin-coating c.a. 2.0 µL of the nanoparticle 
solution (typical concentration: 0.2 mg/mL) onto freshly cleaved mica plates (Ruby clear 
mica, New York Mica Co.) and allowed to dry freely in air.  The number-average particle 
heights (Hav) values and standard deviations were generated from the sectional analysis 
of more than 150 particles from several different regions. 
Hydrodynamic diameters (Dh) and size distributions for the SCKs in aqueous 
solutions were determined by dynamic light scattering (DLS).  The DLS instrument 
consisted of a Brookhaven Instruments Limited (Worcestershire, U.K.) system, including 
a model BI-200SM goniometer, a model BI-9000AT digital correlator, a model EMI-9865 
photomultiplier, and a model 95-2 Ar ion laser (Lexel Corp., Farmindale, NY) operated at 
514.5 nm.  Measurements were made at 20 °C.  Prior to  analysis, solutions were filtered 
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through a 0.22 µm Millex GV PVDF membrane filter (Millipore Corp., Medford, MA) and 
then centrifuged in a model 5414 microfuge (Brinkman Instruments, Inc., Westbury, NY) 
for 10 min to remove dust particles.  Scattered light was collected at a fixed angle of 90°.  
The digital correlator was operated with 522 ratio spaced channels, and initial delay of 5 
µs, a final delay of 100 ms, and a duration of 10 min.  A photomultiplier aperture of 400 
µm was used, and the incident laser intensity was adjusted to obtain a photon counting 
of between 200 and 300 kcps.  Only measurements in which the measured and 
calculated baselines of the intensity autocorrelation function agreed to within 0.1% were 
used to calculate particle sizes.  The calculations of the particle size distributions and 
distribution averages were performed with the ISDA software package (Brookhaven 
Instruments Company), which employed single-exponential fitting, cumulants analysis, 
non-negatively constrained least-squares (NNLS) and CONTIN particle size distribution 
analysis routines.  All determinations were made in triplicate. The results were analyzed 
by UNICORN 3.10.11. 
 Fast protein liquid chromatography (FPLC) was performed on an AKTA (GE) 
system, including a P-920 pump, Columns of Superose 12 10/300 GL, and a UV 
detector with 254 nm wavelength.  The eluent was 20 mM HEPES with 150 mM NaCl 
and flow rate was 0.8 mL/min.  UV- vis spectra were acquired on a Varian Cary 1E UV-
vis system (Varian, Inc., Palo Alto, CA) using polystyrene cuvettes. 
 General Procedures for Diblock Copolymer Preparation. Poly(t-butyl 
acrylate) (PtBA) homopolymer was first prepared by atom transfer radical polymerization 
(ATRP).  PtBA was further used as a macroinitiator to grow the second block, 
polystyrene (PS), through the same polymerization method, to afford poly(t-butyl 
acrylate)-b-polystyrene (PtBA-b-PS).  The resulting PtBA-b-PS was then treated with 
trifluoroacetic acid in methylene chloride to remove the protecting t-butyloxy groups, as 
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monitored by 1H NMR.  After the removal of the solvent, the residue was dissolved in 
tetrahydrofuran and purified by dialysis against water.  PAA-b-PS diblock copolymer was 
obtained after lyophilization. 
PtBA61-b-PS34: 0.83 g (67% yield). GPCMn = 11,600 Da from GPC, Mw/Mn = 1.08.  Tg 
(PtBA) = 53 °C, T g (PS) = 82 °C.  IR: 3433, 3100-2870, 1943, 1870, 18 02, 1734, 1601, 
1493, 1452, 1392, 1368, 1259, 1164, 846, 757, 704, 542 cm-1.  1H NMR (CDCl3, 300 
MHz, ppm): δ 7.25-6.27 (m, 5Ar-H), 2.37-2.02 (br, CH of the polymer backbone), 1.99-
1.08 (br, CH2 of the polymer backbone and C (CH3)3).  13C NMR (CDCl3, 75 MHz, ppm): 
δ 174.0, 125.8-129.7, 108.1, 80.3, 40.4-41.5, 35.5-36.8, 27.9. 
PAA61-b-PS34: 0.44 g (88% yield).  Mn = 8,200 Da.  Tg (PAA) = 126 °C, T g (PS) = 
105 °C.  IR: 3405, 3047-2914, 1942, 1875, 1722, 160 1, 1492, 1450, 1245, 762, 701 cm-
1
. 
1H NMR (THF-d8, 300 MHz, ppm): δ 11.6-10.0 (br, COOH), 7.25-6.30 (m, 5Ar-H), 2.60-
2.20 (br, CH of the polymer backbone), 2.15-1.10 (br, CH2 of the polymer backbone). 13C 
NMR (THF-d8, 75 MHz, ppm): δ 177.5, 124.8-129.5, 41.5-42.6, 35.5-37.2. 
 PtBA60-b-PS60: 4.1 g (80% yield); GPCMn = 14,000 Da, Mw/Mn = 1.15. Tg (PtBA) = 
49 °C, T g (PS) = 93 °C.  IR: 3430, 3100-2890, 1940, 1860, 18 00, 1734, 1600, 1490, 
1452, 1390, 1370, 1260, 1164, 845, 756, 700, 540 cm-1.  1H NMR (CDCl3, 300 MHz, 
ppm): δ 7.23-6.24 (m, 5Ar-H), 2.35-2.05 (br, CH of the polymer backbone), 1.98-1.07 (br, 
CH2 of the polymer backbone and C(CH3)3).  13C NMR (CDCl3, 75 MHz, ppm): δ 173.6, 
126.0-130.2, 108.0, 80.1, 40.6-41.7, 35.5-36.6, 28.0. 
 PAA60-b-PS60: 1.1 g (90% yield). Mn = 10,600 Da.  Tg (PAA) = 126 °C, Tg (PS) = 
104 °C. IR: 3407, 3040-2915, 1940, 1873, 1722, 1600 , 1492, 1453, 1242, 760, 700 cm-
1. 1H NMR (THF-d8, 300 MHz, ppm): δ 12.6-10.4 (br, COOH), 7.20-6.35 (m, 5Ar-H), 
2.58-2.18 (br, CH of the polymer backbone), 2.20-1.10 (br, CH2 of the polymer 
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backbone). 13C NMR (THF-d8, 75 MHz, ppm): δ 177.0, 125.3-130.5, 42.0-42.9, 35.7-
37.0. 
 Preparation of NH2-PEG5000-5-FAM-KCRGDC. Three steps were involved to 
prepare NH2-PEG5000-5-FAM-KCRGDC, as shown in Scheme 1. BocNH-PEG5000-NH2 
(compound 1, 300 mg, 0.0600 mmol), was dissolved in 13 mL of dichloromethane and 
stirred at room temperature for c.a. 0.5 h.  Succinic anhydride (24.6 mg, 0.246 mmol) 
and DIPEA (21.0 µL, 15.5 mg, 0.120 mmol) were added.  The reaction mixture was 
allowed to stir at room temperature for 24 h.  The reaction mixture was then 
concentrated and precipitated into cold ether (40 mL) twice.  The precipitate was dried 
under vacuum to afford 238 mg of white solid as compound 2, BocNH-PEG5000-
NHCOCH2CH2COOH (yield 80%). 
 Compound 2 (201 mg, 0.0402 mmol) was dissolved in 10 mL of dichloromethane 
and stirred at room temperature for c.a. 0.5 h.  N-hydroxysuccinimide (23.6 mg, 0.205 
mmol) and N,N′-Dicyclohexylcarbodiimide (43.7 mg, 0.211 mmol) were added.  The 
solution was allowed to stir at room temperature for 24 h before being concentrated and 
precipitated into cold ether (40 mL) twice.  The precipitate was then dried under vacuum 
to afford a white solid, compound 3 (151 mg, yield: 73%). 
 5-FAM-KCRGDC (40.6 mg, 0.0390 mmol) was dissolved in 5 mL of dry DMF, to 
this solution were also added Compound 3 (104 mg, 0.0201 mmol) and DIPEA (10 µL, 
7.3 mg, 0.057 mmol).  The reaction mixture was allowed to stir at room temperature for 
24 h.  The reaction mixture was precipitated into cold ether (45 mL) once.  The solid was 
then dissolved in DCM and precipitated into cold ether (45 mL) twice to afford a yellow 
solid as compound 4 (100 mg, yield: 80%). 
 Compound 4 (100 mg, 15.9 µmol) was dissolved in 6 mL of DCM.  TFA (4.8 mL, 
7.1 g, 62.3 mmol) was added.  The reaction mixture was allowed to stir at room 
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temperature for 12 h, concentrated and precipitated into cold ether.  The precipitate was 
dried under vacuum to afford NH2-PEG5000-5-FAM-KCRGDC as a yellow solid (80 mg, 
yield: 79%). 
 
 
Scheme 1. Synthesis of NH2-PEG5000-5-FAM-KCRGDC. 
 
General procedures for preparation of mPEG2000-g-PAA-b-PS Block Copolymers.  
Grafting mPEG2000 onto PAA-b-PS involved the following: to a solution of PAA60-b-PS60 
block copolymer in anhydrous (DMF), 1-[3′-(dimethylamino)propyl]-3-ethylcarbodiimide 
methiodide (EDCI), and 1-hydroxybenzotriazole (HOBt) were added, and the reaction 
mixture was allowed to stir for 1 h at room temperature.  Then DIPEA and a solution of 
monoamine terminated mPEG2000 in anhydrous DMF were added and the reaction 
mixture was further stirred for 30 h at room temperature.  The relative ratios of PAA60-b-
PS60 block copolymer/EDCI/HOBt/mPEG-NH2 were varied to alter the grafting densities, 
whereby to achieve grafting densities of 2.5 and 5.5 mPEGs per macromolecule, the 
stoichiometry were 1.0:3.5:3.5:3.5, and 1.0:7.0:7.0:7.0, respectively.  The final grafted 
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block copolymers were isolated by transferring the reaction mixtures to presoaked 
dialysis tubing (MWCO 6000-8000 Da) and dialyzing against nanopure water for 4 d to 
remove the organic solvent and the small molecular byproduct.  The aqueous solutions 
were then lyophilized to afford the products as white solid.  1H NMR (CD2Cl2, 500 MHz, 
ppm): δ 1.20-2.40 (br, -CH2- and -CH- of the polymer backbone), 3.34 (s, mPEG terminal 
-OCH3 protons), 3.42-3.80 (br, mPEG backbone -OCH2CH2O- protons), 6.16-7.11 (br, 
aromatic protons). 
mPEG20002.5-g-PAA57.5-b-PS60.  PAA60-b-PS60 (120.0 mg, 11.3 µmol), EDCI (11.8 
mg, 39.6 µmol), HOBt (5.4 mg, 40.0 µmol), and monoamine terminated mPEG2000 
(79.2 mg, 39.6 µmol) in anhydrous DMF (15.0 mL). Yield: 75%. 
mPEG20005.5-g-PAA54.5-b-PS60.  PAA60-b-PS60 (110.0 mg, 10.4 µmol), EDCI (21.6 
mg, 72.8 µmol), HOBt (9.9 mg, 73.3 µmol), and monoamine terminated mPEG2000 
(145.6 mg, 72.8 µmol) in anhydrous DMF (15.0 mL). Yield: 75%. 
Preparation of mPEG2000-g-DOTA-lysine-g-PAA-b-PS Block Copolymers.  The 
DOTA-lysine (a lysine derivative for 1,4,7,10-tetraazocyclododecane-N,N′,N′′,N′′′-
tetraacetic acid, DOTA) was grafted onto mPEG2000-g-PAA-b-PS by following a 
procedure similar to that used to graft mPEG2000 (described above).  To a solution of 
mPEG2000-g-PAA-b-PS block copolymer (10.3 µmol) in anhydrous DMF (10.0 mL), 
EDCI (11.6 mg, 39.1 µmol) and HOBt (5.3 mg, 39.3 µmol) were added and the reaction 
mixture was allowed to stir for 1 h at room temperature.  Then a solution of DOTA-lysine 
(trifluoroacetic acid (TFA) salt, 23.1 mg, 39.2 µmol) and N,N-diisopropylethylamine 
(DIPEA, 25.4 mg, 0.196 mmol) in anhydrous DMF (2.0 mL) was added and the reaction 
mixture was further stirred for 30 h at room temperature.  The final grafted block 
copolymers were isolated by transferring the reaction mixtures to presoaked dialysis 
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tubing (MWCO 6000-8000 Da) and dialyzing against nanopure water for 5 d to remove 
the organic solvent and the small molecular byproduct.  The aqueous solutions were 
then lyophilized to afford the products as white solid.  Yield: 65%. 1H NMR (500 MHz, 
CD2Cl2 with 2 drops of CF3CO2D, ppm): δ 1.20-2.40 (br, -CH2- and -CH- of the polymer 
backbone, overlapped with DOTA-lysine protons), 2.40-2.70 (br, DOTA-lysine 
macrocyclic protons), 3.34 (s, mPEG terminal -OCH3 protons), 3.42-3.80 (br, mPEG 
backbone -OCH2CH2O- protons), 6.16-7.11 (br, aromatic protons). 
Preparation of PEG-5-FAM-KCRGDC-g-mPEG2000-g-DOTA-lysine-g-PAA-b-PS 
Block Copolymers.  The PEG-5-FAM-KCRGDC was grafted onto mPEG2000-g-DOTA-
lysine-g-PAA-b-PS by following the procedures similar to used to graft mPEG2000 or 
DOTA-lysine (described above).  The relative ratio of mPEG2000-g-DOTA-lysine-g-PAA-
b-PS block copolymer/EDCI/HOBt/mPEG-NH2 was 1:20:20:4.  To a solution of 
mPEG2000-g-PAA-b-PS block copolymer (0.80 µmol) in anhydrous DMF (7.5 mL), EDCI 
(4.96 mg, 16.7 µmol) and HOBt (2.27 mg, 16.8 µmol) were added and the reaction 
mixture was allowed to stir for 1 h at room temperature.  Then a solution of PEG-5-FAM-
KCRGDC (trifluoroacetic acid (TFA) salt, 21.1 mg, 3.36 µmol) and N,N-
diisopropylethylamine (DIPEA, 100 mg, 0.85 mmol) in anhydrous DMF (2.0 mL) was 
added and the reaction mixture was further stirred for 24 h at room temperature.  The 
polymer concentration of the reaction mixture was then adjusted to 1.00 mg/mL by 
adding appropriate amount of DMF for future use.  Micelles were directly prepared from 
the reaction mixture and impurities were later removed by dialysis against nanopure 
water in MWCO 50000 Da dialysis tubings. 
Preparation of HOOC-PEG30004.0-g-DOTA-lysine3.2-g-PAA60-b-PS60 Block 
Copolymer. Similar procedures were followed as mentioned above, except for the 
attaching sequence, as shown in the scheme below: DOTA-lysine (tetra-t-butyl ester) 
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was first grafted onto the block copolymer PAA60-b-PS60, solid polymer product, was 
obtained by methods described above and the number of DOTA-lysine per polymer 
chain was determined by 1H NMR (coupling efficiency 90%).  To the DOTA-lysine(tetra-t-
butyl ester)-g-PAA60-b-PS60 was then attached NH2-PEG3000-COOH, by pre-activating 
the –COOH on the polymer chains, to afford HOOC-PEG30004.0-g-DOTA-lysine3.2-g-
PAA60-b-PS60 (coupling efficiency 80%). 
 
 
Scheme 2. Preparation of HOOC-PEG30004.0-g-DOTA-lysine3.2-g-PAA60-b-PS60. 
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General procedures for micelle assembly and SCK formation. To a solution of 
the amphiphilic block copolymer (PAA-b-PS, mPEG2000-g-DOTA-lysine-g-PAA-b-PS or 
PEG-5-FAM-KCRGDC-g-mPEG2000-g-DOTA-lysine-g-PAA-b-PS) in THF or DMF, (ca. 
1.0 mg/mL in polymer concentration), an equal volume of nanopure water was added 
dropwise via a syringe pump over 6 h.  The reaction mixture was further stirred for c.a. 
16 h at room temperature before transferring to a presoaked dialysis tubing (MWCO. 
6,000-8,000 Da for PAA-b-PS; MWCO 50,000 Da for PEG-5-FAM-KCRGDC-g-
mPEG2000-g-DOTA-lysine-g-PAA-b-PS), and dialyzed against nanopure water for 4 
days, to afford a micelle solution with the final polymer concentration of 0.20-0.30 
mg/mL. 
General procedures for the PAA Block Crosslinking to Form SCKs.  To a 
solution of micelle in nanopure water, was added dropwise a solution of 2,2’-
(ethylenedioxy)bis(ethylamine) (c.a. 1.0 mg/mL) in nanopure water over 10 min.  The 
reaction mixture was stirred for c.a. 2 h at room temperature.  To this solution, was 
added dropwise via syringe pump over 30 min, a solution of 1-[3’-
(dimethylamino)propyl]-3-ethylcarbodiimide methiodide in nanopure water.  The reaction 
mixture was further stirred 20 h at room temperature before transferring to a presoaked 
dialysis tubing, and dialyzed against nanopure water for 4 days, to remove all of the 
impurities and afford the SCK solution.  The nominal crosslinking extent (20% and 50%) 
were based on the stoichiometry of the crosslinker (2,2’-(ethylenedioxy)bis(ethylamine)) 
to that of the carboxylic acids on the PAA domain.  The general stoichiometry employed 
to achieve 20% nominal crosslinking was 9:2.2:1 for carboxylic acid units : EDCI : 
crosslinker, and to achieve 50% nominal crosslinking, the stoichiometry was 3.6:2.2:1. 
General procedures for post-attaching KCRGDC/5-FAM-KCRGDC/PEG-5-FAM-
KCRGDC onto micelle/SCK nanoparticles.  All micelle/SCK samples were pre-cooled 
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to 4 °C.  Sulfo-NHS aqueous solution was then added, and the containers were shaken 
for c.a. 30 min.  Freshly prepared EDCI aqueous solution was added and the reaction 
containers were shaken for 1.5 h in a 4 °C refrigerator.  Here, the pH values of the 
solutions were adjusted to around 7.4 with pH 9.2 0.2 M phosphate buffer.  KCRGDC/5-
FAM-KCRGDC/PEG-5-FAM-KCRGDC solutions were then added.  The pH of the 
reaction solutions were finally adjusted to around 7.4 (optimal pH for the coupling 
reaction to occur) and the reaction mixtures were kept shaking at 4 °C for 24 h.  All 
reaction mixtures were then dialyzed against pH 7.4 5 mM PBS (after treatment of 
Chelax 100 resin) for 5 d. 
Reduction of disulfide bond on KCRGDC-NP to thiol.  Excess DTT (DL-
dithiothreitol) was incubated with micelle/SCK nanoparticles labeled with the cyclic 
KCRGDC at 45 °C for 1h (Scheme 3).  The reaction mixture was then dialyzed against 
nanopure water in pre-soaked MWCO 6-8000 Da dialysis tubing to remove unreacted 
DTT and for later quantification of thiol groups by Ellman’s assay.   
 
 
Scheme 3. Cleavage of disulfide bond on KCRGDC. 
 
Ellman’s assay. Cysteine (26.0 mg) is dissolved into 10.00 mL of reaction buffer 
(0.10 M sodium phosphate buffer, pH 8.0) to make the stock solution.  Ellman’s reagent 
(4.00 mg DTNB) was dissolved into 1.00 mL of reaction buffer.  A series of cysteine 
standard solutions with different concentrations are then prepared from the stock 
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solution, with cysteine concentrations being 15.0 mM, 1.50 mM, 1.25 mM, 1.00 mM, 1.00 
mM, 0.75 mM, 0.50 mM, 0.25 mM and 0.05 mM.  The Ellman’s reagent solution was 
then mixed with the cysteine standard solutions and the samples to be measured using 
the following volumetric quantities: 983 µL buffer and 18 µL Ellman’s reagent for blank; 
938 µL buffer, 18 µL of Ellman’s reagent, and 45 µL sample. After 15 minutes the 
absorbance of each sample was measured at 412 nm.  
Purifying aqueous nanoparticle samples using Sephadex® G75 gravity SEC 
columns. Sephadex® G75 resin (superfine) (10 g) was pre-soaked in boiling water for 
c.a. 30 min to form a gel.  After cooling to room temperature, the resin was packed into a 
glass column (30 cm × 2 cm) equipped with a stopcock.  About 200 mL of the eluent 
(150 mM PBS, pH ~ 7.4) was passed through the column prior to any sample loading.  
For each run, c.a. 4 mL of nanoparticle samples (with polymer concentration around 
0.20-0.30 mg/mL) was loaded.  The separation process was monitored by UV 
spectrometry.  Columns were reused after being flushed with excess eluent.  The 
desired fractions were collected and concentrated and solvent-exchanged into 5 mM 
PBS by using Centricon (MWCO 10000 Da, Millpore, MA) tubes. 
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vivo studies of 64Cu(II)-labeled cross-bridged tetraazamacrocycle-amide complexes as 
models of peptide conjugate imaging agents.” J. Med. Chem. 2007; 50 (10): 2527-2535. 
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